Verified news coverage spanning food allergy, celiac, FPIES, alpha-gal, EoE, and asthma — from the United States and across the globe. Sourced from real news media and stored in our database, linked to the original articles.
News items are compiled via live web search from real news outlets and stored in our database. Headlines, dates, and links point to the original sources — always verify details by reading the full article. This feed is for awareness only and is not medical advice.
The American Academy of Allergy, Asthma & Immunology conditions library overview of fire ant allergy — symptoms, diagnosis, and treatment options for this serious stinging-insect allergy.
New Medscape coverage finds abrocitinib alters the skin microbiome of patients with atopic dermatitis — shedding light on how JAK-1 inhibition may reshape the cutaneous ecosystem underlying allergic skin disease.
A JAMA Insights review by Stahl, Jansson-Knodel, and Leonard compares the latest guideline recommendations (ESsCD 2025, ACG 2023, ESPGHAN 2020) for serology-based vs biopsy-confirmed celiac disease diagnosis in adults and children — including when a no-biopsy diagnosis is appropriate.
Dr. David Stukus (ACAAI president-elect) explains how flu, RSV, COVID-19, pneumococcal, and pertussis vaccines protect people with asthma and COPD from severe fall and winter respiratory infections — timed for National Immunization Awareness Month.
A landmark Nature study led by Yale's Dr. Noah Palm and supported by the Food Allergy Science Initiative finds that Bifidobacterium from dietary milk trains the infant immune system \u2014 a possible link between breast milk bacteria and increased immune defenses against food allergy.
New York's Elijah's Law is expanding to require stock epinephrine training in childcare settings — honoring the legacy of Elijah Silvera and strengthening early-childhood anaphylaxis preparedness across the state.
Read full article on Allergic Living500 articles
A clinical trial led by Dr. Kari Nadeau aimed at preventing food allergies in 800 infants is at risk of termination due to federal research funding cuts, potentially endangering patient safety and progress in allergy prevention.
A wrongful death lawsuit has been filed against a grocer and a bakery following the death of a 25-year-old dancer who suffered a fatal anaphylactic reaction to a mislabeled cookie containing peanuts.
The FDA has approved an Investigational New Drug application for LongBio's next-generation anti-IgE antibody, LP-003, to begin clinical trials for the treatment of food allergies.
A nationwide clinical trial led by Stanford Medicine researchers demonstrated that children and young adults with multiple food allergies can safely consume full servings of foods they were previously allergic to following specific treatment protocols.
A mother and her son filed a complaint with the Department of Transportation after being removed from an Allegiant Air flight following a request for nut allergy accommodations.
FARE reported on the progress of the Alpha-gal Expert Advisory Council as they work to build a strategic foundation for addressing Alpha-gal syndrome.
Two new federal bills have been introduced to support those with Alpha-gal syndrome, including legislation that would require alpha-gal to be listed on food labels and increase federal funding for tick-borne disease research.
A study published in The Journal of Allergy and Clinical Immunology: In Practice reviewed 1,275 Australian infants referred to public hospitals after reacting to peanut before their first birthday; 778 later had a supervised oral food challenge about six months after that first reaction. Nearly 35% (271 infants) completed the challenge without any reaction, meaning many suspected peanut allergies in infancy may be misdiagnosed. Of the 507 who did react, 61 developed anaphylaxis and were treated with epinephrine. Experts quoted in the coverage urge a supervised food challenge, performed by an allergist with anaphylaxis treatment on hand, when an infant's peanut allergy diagnosis is uncertain.
Recent research highlights a new antibody-based strategy aimed at retraining the immune system to tolerate food allergens. This approach offers potential hope for children who are too sensitive to traditional oral immunotherapy.
FARE criticized a Super Bowl commercial for Uber Eats that used a peanut allergy reaction as a punchline. Following public outcry from the allergy community, the company removed the specific depiction from the advertisement.
AAFA participated in The Respiratory SUMMIT 2026 to discuss patient and policy perspectives on the prevention of chronic respiratory diseases.
The AAAAI provides safety guidance for Halloween, reminding parents to check labels on fun-size candy and carry epinephrine.
A retrospective analysis of US military data from 2017 to 2024 indicates that severe food allergy-related emergencies during deployment are rare. The findings suggest that current military accession policies regarding food allergies may warrant reassessment.
SnackSafely.com introduced a new service aimed at improving transparency regarding food allergens for consumers. The initiative focuses on providing clearer information about shared lines and facilities to help those with food allergies make safer choices.
Television personality Jo Frost shares her personal experience with anaphylaxis to raise awareness about the severity of food allergies. The article highlights the importance of preparedness and public education regarding life-threatening allergic reactions.
Following the FDA approval of lab-grown salmon, this article examines the implications for individuals with fish allergies. It discusses whether these products pose similar risks to traditional seafood and what labeling requirements apply.
A retrospective cohort study of over 10,000 adults found that many patients eligible for biologics experienced sustained improvement in asthma exacerbations without initiating biologic therapy.
A summary of pediatric clinical trial results from October 2026, including data showing that tezepelumab sustains remission in eosinophilic esophagitis (EoE) through 52 weeks.
The AAFA warns that DIY food allergy test kits are inaccurate and potentially harmful, advising against their use for diagnosis.
A major food allergy clinic network has opened a new location in Great Neck, New York, to provide specialized care for families managing food allergies. The facility is led by board-certified allergists to address the growing need for expert allergy management in the region.
Advocates are criticizing a proposed FAA rule that leaves uncertainty regarding the mandatory inclusion of epinephrine in airline emergency medical kits. The community is calling for the FAA to require epinephrine rather than suggesting it as an optional medication for anaphylaxis.
A clinical trial found that omalizumab (Xolair) was more effective and better tolerated than oral immunotherapy for treating multi-food allergies. Participants showed a higher ability to consume multiple allergens without reaction compared to those on OIT.
Long-term follow-up data from the LEAP-Trio study confirms that introducing peanut products in infancy provides lasting protection against peanut allergy through adolescence, regardless of how often peanut is consumed later in childhood.
The FDA approved omalizumab for the reduction of allergic reactions to accidental food exposure in adults and children aged 1 year and older. The approval was supported by data from the NIAID-funded OUtMATCH clinical trial.
A new study shows that a specific therapy allows children with high-threshold peanut allergy to safely consume significant amounts of peanut butter. This provides a new management option for children who previously had to rely solely on strict avoidance.
This report highlights the geographic expansion of alpha-gal syndrome and the increasing evidence that vectors other than the lone star tick may be involved. It emphasizes the need for clinicians to recognize the condition, which is often misdiagnosed as other gastrointestinal disorders.
A study found that Black race was the strongest factor associated with high T-helper 2 inflammation in children with severe asthma, even after adjusting for social and environmental variables.
Research published in Pediatric Allergy and Immunology indicates that increased weekly exposure to ambient fine particulate matter correlates with higher symptom severity scores in pediatric patients with chronic rhinitis.
The FDA has approved new berotralstat pellets for the treatment of hereditary angioedema, expanding options for older patient populations.
The Asthma and Allergy Foundation of America announced that BEHR ECOMIX paint has received the Asthma & Allergy Friendly certification for its low VOC content.
AAFA promoted their educational resources for pediatricians, including action plans for asthma and food allergy anaphylaxis, at the AAP 2026 conference.
AAFA recognized October as Eczema Awareness Month to highlight the impact of the condition on patients.
A vaccine delivering allergen-specific mRNA via lipid nanoparticles reduced allergic responses in mice, report researchers at Cincinnati Children's and the University of Pennsylvania led by Marc Rothenberg and Drew Weissman. Treated mice exposed to allergens showed less airway swelling and inflammation and produced allergen-specific antibodies known to block allergic reactions, in both preventive and established-allergy models. The team calls allergen-specific mRNA-LNP therapy a promising approach that could apply to multiple types of allergy, including food allergy, and may offer an alternative to routine allergy shots.
A report by Nutritics indicates that the restaurant industry loses billions annually due to unclear or missing allergen information on menus. The study notes that a significant percentage of diners with food allergies avoid establishments that fail to provide transparent allergen disclosures.
The FDA announced a series of virtual public meetings to discuss the potential implementation of food allergen thresholds. These discussions are intended to help the agency establish standardized, science-based criteria for allergen labeling on food products.
The FDA convened an expert panel to discuss current challenges and advancements in food allergy management. The meeting included participation from leading researchers and advocacy organizations to inform future regulatory and clinical approaches.
The FDA escalated GF Blends' gluten-free flour recall to Class I on Oct. 28, 2026, its most serious category, after three products were found to potentially contain undeclared wheat gluten. Truly AIP All Purpose Baking Mix Flour, Truly AIP Rustic Bread Mix, and EAT G.A.N.G.S.T.E.R. Pizza Crust and Flat Bread Mix were labeled gluten-free but tested above the FDA's 20 ppm gluten limit — traced to a plantain flour ingredient a supplier certified as gluten-free. The products were sold nationwide online, and the recall remains ongoing.
New research from Japan indicates that cofactors, most notably exercise, are implicated in approximately 50 percent of severe food-induced anaphylaxis cases in adults. The study suggests that identifying these triggers is crucial for understanding why reactions vary in severity.
A nationwide clinical trial led by Stanford Medicine researchers found that omalizumab can help children and young adults with multiple food allergies safely consume foods they were previously allergic to. The study highlights that treatment goals vary by patient, offering multiple paths to living safely with food allergies.
A family has settled a lawsuit against a Florida school district following the death of a student who suffered a fatal allergic reaction after being served food containing nuts. The case highlights the critical importance of strictly following established food allergy management and prevention plans in schools.
A two-year integrated analysis published in The Lancet Respiratory Medicine evaluates the long-term safety and efficacy of depemokimab for patients with type 2 asthma characterized by an eosinophilic phenotype.
The Allergy & Asthma Network promoted their annual advocacy day on Capitol Hill to push for improved policies and patient access to care.
Southwest Airlines faced backlash from the food allergy community after announcing the introduction of pistachios as a snack in certain seating areas. Advocates expressed concern that this move compromises the safety of passengers with nut allergies.
New research from Japan indicates that cofactors, most notably exercise, are implicated in approximately 50 percent of severe food-induced anaphylaxis cases in adults. The study highlights how external factors can significantly worsen allergic reactions.
A pooled analysis presented at CHEST 2026 found that tezepelumab significantly reduced asthma exacerbations in patients regardless of their blood neutrophil or eosinophil counts.
Food Allergy Research & Education (FARE) raised over $1 million at its 2026 gala to support initiatives aimed at preventing, managing, and curing food allergies. The organization continues to advocate for policy changes, such as including infant-safe allergenic foods in WIC packages and expanding food service training programs.
The FDA announced a proposed rule updating nutrient requirements for infant formula, which HHS called the first major update to formula standards in nearly 30 years. The rule would revise requirements for vitamin A, vitamin D, iodine and manganese, reaffirm limits for chloride, potassium, selenium and sodium, and seek public comment on whether to require ingredients such as ARA, DHA and L-carnitine. Additional phases will review the remaining required nutrients and carbohydrate sources, with one final rule to follow; the FDA also released contaminant-testing data showing low or non-detectable chemical levels in most formula samples.
An 8-year-old boy in Ontario passed away following a severe allergic reaction to a frozen dairy treat. The tragedy has prompted renewed reminders for families and food servers to rigorously verify ingredients for those with life-threatening allergies.
A recent study indicates that while the eczema medication Dupixent (dupilumab) can lower IgE levels associated with food allergies, it may paradoxically increase the risk of allergic reactions in some patients.
Novartis has launched a Phase 3 clinical trial for the drug remibrutinib, a pill being tested for its ability to protect against allergic reactions to peanut, milk, and egg in teens and adults.
Disney World has introduced a dedicated food allergy ordering station at EPCOT to help guests with dietary restrictions navigate dining options more safely and efficiently. The station aims to reduce the stress of explaining allergies to staff by providing a specialized service point.
The FAA has released a proposed rule to modernize emergency medical kits on U.S. flights, but critics argue the move toward a flexible, performance-based standard fails to guarantee the presence of modern epinephrine administration devices.
DBV Technologies has submitted a biologics license application to the FDA for its Viaskin peanut allergy patch, intended for children ages 4 to 7. The patch delivers small amounts of peanut protein through the skin to gradually increase tolerance.
Results from the NIAID-funded OUtMATCH trial indicate that omalizumab is more effective than traditional oral immunotherapy for children with multiple food allergies. The study showed the drug significantly increased the amount of various allergens children could consume safely.
A study conducted in Italy found that Xolair (omalizumab) allowed a majority of children with food allergies to consume allergens without reaction. The findings align with U.S. research supported by the NIH regarding the drug's efficacy in desensitization.
The NIH announced a clinical trial to assess an experimental treatment designed to prevent life-threatening allergic reactions in individuals with multiple food allergies. The study aims to help patients tolerate small amounts of allergens consumed unintentionally.
A study supported by the NIAID found that a specific therapy enabled children with high-threshold peanut allergies to safely consume significant amounts of peanut butter. This provides a new management option for children who previously relied solely on strict avoidance.
Researchers at the NIH have discovered rare antibodies that act as a biological shield against alpha-gal syndrome. This finding could lead to new interventions for the tick-bite-associated allergy, which currently has no cure.
The CDC provides guidance on managing alpha-gal syndrome, emphasizing the importance of identifying and avoiding products containing alpha-gal. It notes that new tick bites may reactivate allergic reactions and advises patients to work with allergists to prepare for potential anaphylaxis.
Walt Disney World has implemented updates to its food allergy guidance specifically regarding tree nuts. The update aims to clarify safety protocols for families visiting the parks.
A new report provides updated, comprehensive recommendations for schools to manage food allergies, including staff training, stock epinephrine, and emergency protocols. The guidance was developed by FARE in collaboration with medical and disability rights experts.
The Xolair biosimilar Omlyclo, which is FDA-approved for the treatment of four allergic and inflammatory conditions, is now commercially available in the United States.
This study analyzes patient-reported symptoms and the diagnostic burden of Alpha-gal syndrome. It highlights that current management relies primarily on strict avoidance of alpha-gal containing products due to a lack of preventative treatments.
After advocacy from the nonprofit FARE, Uber Eats agreed to edit a Super Bowl commercial that featured an insensitive depiction of a life-threatening peanut allergy.
The AAFA highlights the prevalence of asthma and allergic conditions in the U.S. and emphasizes the importance of community support in managing these health issues.
Moonlight Therapeutics has received FDA clearance to begin clinical testing of MOON101, a treatment for peanut allergy. The trial is supported by a $3 million grant from the National Institute of Allergy and Infectious Diseases.
A multicenter study published in the Journal of Investigational Allergology & Clinical Immunology evaluates the real-world effectiveness and clinical remission rates of tezepelumab in patients with severe asthma.
The ASCENT study demonstrates that patients with severe, uncontrolled asthma treated with tezepelumab show clinically meaningful improvements in lung function and quality of life within 24 weeks.
The Asthma and Allergy Foundation of America highlights the importance of using certified products to reduce indoor triggers for asthma, allergies, and eczema.
The CDC published data on the seroprevalence of Alpha-gal syndrome among blood donors across 10 states. The report characterizes the condition as an emerging, noninfectious tickborne disease that causes allergic reactions to red meat and mammalian products.
A study conducted in Romania found that while 17.6% of adults self-reported a food allergy, only 6.6% were confirmed via testing. The research also highlighted a significant gap in knowledge regarding anaphylaxis treatment, with fewer than half of participants identifying adrenaline as the first-line therapy.
The FDA is considering a shift toward a threshold-based system for food allergen labeling, which would estimate doses at which 95 percent of allergic individuals are protected. Public comments on this potential regulatory change are open through May 19, 2026.
Pennsylvania lawmakers are advancing House Bill 77, which aims to improve restaurant safety for diners with food allergies. The bill would require establishments to provide written allergen notices and display awareness posters for staff.
The CDC projects that the 2026-2027 respiratory illness season will see similar peak hospitalization levels for COVID-19, flu, and RSV as the previous year.
The FDA approved Xolair (omalizumab) as the first medication to reduce the risk of allergic reactions to multiple foods following accidental exposure. The treatment is intended for IgE-mediated food allergies but is not a cure and does not replace the need for strict allergen avoidance or emergency epinephrine.
Opinion column from Steritech food-safety vice president Chris Boyles on the allergen-labeling burden shifting to restaurants. It notes California's SB 68 took effect July 1, 2026, requiring chains with 20 or more U.S. locations to disclose in writing which of the nine major food allergens are in each menu item served in the state, and that FDA Food Code provision 3-602.12(C) - carried into the 2026 Food Code released Sept. 17 - directs operators to notify guests in writing about major food allergens in unpackaged food. The piece argues a single entrance sign is not enough and that multistate operators need one documented allergen-management system spanning buyers, suppliers, menus, and staff.
A new microneedle patch device for peanut allergy has entered clinical trials with support from the NIAID. The device aims to provide a multi-food allergen treatment option for both children and adults.
The article examines proposed research initiatives regarding vaccines and food allergies, noting that the scientific community maintains skepticism toward claims linking the two.
Beyond Celiac shared positive phase 2 clinical trial results for FB102, an investigational treatment for celiac disease.
The food allergy community is expressing concern over proposed FAA rules regarding emergency medical kits on airplanes. Advocates are pushing for mandatory epinephrine auto-injectors to be included in all kits to better manage anaphylaxis during flights.
A family has filed a lawsuit following the death of a teenager who suffered a fatal allergic reaction to an airline meal. The suit alleges deficiencies in crew training and a lack of comprehensive allergen labeling requirements for in-flight food.
Following the FDA's approval of Xolair for food allergies, pharmaceutical companies are now working on biosimilar versions. This development is expected to expand treatment options and potentially increase accessibility for patients.
New federal legislation, the Protecting Children with Food Allergies Act, mandates that school food service staff undergo specific food allergy training. The law aims to improve safety protocols and emergency response capabilities in schools nationwide.
A social media influencer passed away after suffering a severe allergic reaction at a promotional event. Reports indicate the food item consumed was allegedly misidentified as safe, highlighting the critical need for better ingredient transparency in food service.
Following the death of a student due to a food allergy, parents are advocating for stricter restaurant labeling requirements. The case underscores the ongoing challenges in ensuring consistent allergen communication in the food service industry.
The American Lung Association has launched the COPD-OMA trial to investigate whether the asthma medication omalizumab can reduce flare-ups in COPD patients sensitized to indoor allergens.
Alpha-gal syndrome, a tick-borne meat allergy, continues to present challenges as tick season persists. The condition is shifting traditional understandings of food allergy management and diagnosis.
The Allergy & Asthma Network is hosting its 12th annual USAsthma Summit to address national challenges in asthma care. The event focuses on policy, research, and improving access to care for millions of Americans.
A family is suing an airline following the death of a teenager who suffered a fatal allergic reaction to an in-flight meal. The lawsuit alleges deficiencies in crew training and a lack of adequate emergency medical procedures for passengers with food allergies.
A new sublingual immunotherapy (SLIT) tablet for peanut allergy has shown promise in Phase 2 trials by increasing patient tolerance. The treatment is now advancing to Phase 3 clinical trials to further evaluate its safety and efficacy.
A new clinical trial is testing a potential rival to Xolair that aims to provide protection against multiple food allergies with less frequent dosing. The study is enrolling patients to evaluate the drug's ability to prevent allergic reactions.
Beyond Celiac shared positive phase 2 clinical trial results for FB102, a potential new therapeutic treatment for celiac disease.
A comprehensive review of 190 studies involving 2.8 million children identified infant eczema, delayed introduction of allergenic foods, and early antibiotic use as key risk factors for developing food allergies.
Novartis halted a Phase 3 study of the biologic drug ligelizumab for peanut allergy to implement an optimized dosing regimen. The company stated the decision was not related to safety concerns and plans to restart the study.
Disc Medicine announced positive late-stage trial results for its drug candidate designed to treat erythropoietic protoporphyria, a rare condition often described as a severe sun allergy.
Data published in CHEST indicates that 70% of adults eligible for biologic therapy achieved a reduction in yearly asthma exacerbations through standard care alone. The study suggests that many patients may see significant improvements without immediate escalation to biologics.
Rep. Bob Onder (R-MO) highlights a July recall of cetirizine (generic Zyrtec) contaminated during manufacturing in India, arguing America's heavy dependence on overseas pharmaceutical production (80%+ of drug ingredients) is a national security vulnerability. The Trump administration ended advance notice for foreign FDA inspections and signed an executive order promoting domestic manufacturing of critical medicines, with Missouri's Sentio BioSciences partnering to rebuild U.S. drug ingredient production.
Researchers at Imperial’s National Heart & Lung Institute have reported positive safety and tolerability results from a Phase 1 trial of a new peanut allergy vaccine using virus-like particle technology.
A global food safety body has established a new risk-based approach for precautionary allergen labeling (PAL). The goal is to make 'may contain' warnings more consistent and science-based for consumers worldwide.
Researchers have established Canada's first FPIES registry to better understand this non-IgE-mediated food allergy. The study provides insights into the condition's prevalence and the need for increased clinical awareness.
Novartis halted a Phase 3 study of the biologic drug ligelizumab for peanut allergy to implement an optimized dosing regimen. The company stated the decision was not related to safety concerns and plans to restart the study in late 2024.
SnackSafely warns the community about viral social media posts falsely claiming that a single-dose vaccine has been developed to permanently cure peanut allergies. These claims are fabricated and not supported by any legitimate medical research.
Researchers at Imperial’s National Heart & Lung Institute reported positive safety and tolerability results from a Phase 1 trial of a new peanut allergy vaccine using virus-like particle technology. The study was published in the Journal of Allergy and Clinical Immunology.
FARE announced participation in a congressional briefing to discuss evidence-based developments in food allergy prevention and the need for increased federal research funding. The event highlights the rising prevalence of food allergies affecting over 33 million Americans.
The NIH released updated federal guidelines for asthma management, focusing on tailored interventions based on age and disease severity. The recommendations include new guidance on using allergy shots and reducing indoor asthma triggers.
Research published in the journal Allergy suggests that exposure to dogs may help reduce food allergy risk in children by influencing immune system development. The study indicates that children with food sensitivities may experience a developmental lag in their immune response.
Palforzia, the first FDA-approved oral immunotherapy for peanut allergy, is set to be discontinued in July 2026. The article discusses alternative treatment options for patients, including emerging biologic therapies.
A study found that an existing FDA-approved asthma drug was effective in blocking life-threatening food allergy reactions in mice. This research highlights a potential new pathway for treating severe food allergies.
A study published in JAMA Pediatrics examined 190 studies involving 2.8 million people to identify risk factors for food allergies. The research confirmed that the risk of a child developing a food allergy is relatively low and found no association between vaccines and food allergy development.
The NIAID continues to support major research initiatives, including the Inner-City Asthma Consortium and the Asthma and Allergic Diseases Cooperative Research Centers, to study the pathogenesis and treatment of asthma.
A recent study explores Food Protein-Induced Enterocolitis Syndrome (FPIES), highlighting that many children can tolerate baked forms of trigger foods like egg and milk. The research also indicates that many children eventually outgrow this condition.
New federal legislation mandates that school food service personnel receive annual training on managing food allergies. The law aims to improve safety for the estimated six million children in the U.S. living with food allergies.
Mondelēz Global LLC issued a voluntary recall for belVita breakfast products due to undeclared peanut contamination caused by cross-contact on a manufacturing line. The incident highlights ongoing concerns regarding allergen labeling and manufacturing safety.
The Protecting Children with Food Allergies Act has been signed into law, requiring school food staff to undergo mandatory allergy training. Experts note this is critical as 20 percent of school epinephrine administrations involve children with undiagnosed allergies.
A large real-world study indicates that semaglutide, the active ingredient in Ozempic and Wegovy, is associated with a 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups.
The FDA approved Novartis Rhapsido (remibrutinib), an oral BTK inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines, making it the only prescription treatment approved for both of the two most common forms of chronic hives (CSU and SD). Phase III RemIND trial showed 29.3% of patients achieved complete hive resolution by Week 12 vs 14.0% on placebo.
Eton Pharmaceuticals acquired exclusive U.S. commercialization rights to LIBERVANT (diazepam) buccal film, an Orphan Drug-designated rescue treatment for seizure clusters in epilepsy patients. Market research showed 71% of patients preferred buccal film over nasal spray, with commercial launch anticipated in April 2027 pending final FDA approval.
Official FDA reference page for the Federal Food, Drug, and Cosmetic Act (FD&C Act), the foundational federal statute codified in Title 21 Chapter 9 of the U.S. Code that authorizes FDA to regulate food, drugs, cosmetics, and medical devices, including allergen labeling requirements for packaged foods.
IgGenix announced that Phase 1 clinical trials for its monoclonal antibody-based therapeutic candidate, IGNX001, are scheduled to begin in Australia. The treatment is designed to provide protection against allergen exposure more rapidly than traditional methods.
Moonlight Therapeutics has initiated a Phase I clinical trial, known as the SURVEYOR study, to evaluate the safety and tolerability of its MOON101 microneedle therapy for peanut allergy. This marks the program's transition from preclinical research to human clinical testing.
IgGenix presented data at the 2024 EAACI Annual Meeting regarding its monoclonal antibody-based therapeutic candidate for peanut allergy. The company utilized its proprietary antibody discovery platform to develop a treatment aimed at blocking the allergic cascade.
A large real-world study found that semaglutide, the active ingredient in Ozempic and Wegovy, is associated with a nearly 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups.
Familiar Halloween candies may have a different recipe, ingredient list, or allergen warning this year. Allergists warn that fun-size and miniature candies can contain different ingredients and carry greater cross-contact risks than their full-size counterparts, so parents of children with food allergies should re-check labels before letting kids dig into their trick-or-treat haul.
The family of Mia St Hilaire, a 12-year-old who died after drinking a milkshake made in an unwashed blender containing hazelnut residue at a London cafe, are calling for a dedicated allergy management rating for food businesses, separate from food hygiene ratings. The cafe was fined £18,000 and its proprietor given community service for Food Safety Act violations.
A fatality has been confirmed linked to Alpha-gal syndrome, a tick-borne condition that causes a severe allergic reaction to red meat. The report highlights the increasing public health concern regarding this allergy.
Virginia has introduced new legislation requiring restaurants to use specific identifying markers on takeout orders when a customer has communicated a food allergy or sensitivity. The law aims to improve communication and safety for diners with dietary restrictions.
Research indicates that baked milk oral immunotherapy is a safe and effective treatment for children with severe cow's milk allergies. The study suggests this method helps build tolerance in allergic patients.
The Global Initiative for Asthma (GINA) released updated 2026 guidelines for the management of asthma in adults and adolescents. The update includes new flowcharts for the assessment and treatment of patients experiencing acute exacerbations, as well as revised guidance on oxygen therapy.
Recent data presented at the ERS 2026 Congress indicates that RSV vaccination demonstrates high effectiveness in preventing complications in patients with COPD.
Medical experts are highlighting the importance of recognizing alpha-gal syndrome, a tick-borne meat allergy, as tick season remains active. Patients experiencing unexplained gastrointestinal symptoms after tick exposure are encouraged to seek evaluation for this condition.
FARE released a comprehensive report supported by the CDC detailing the prevalence, economic burden, and treatment gaps for the 33 million Americans living with food allergies. The report highlights that nearly half of adults with food allergies developed at least one during adulthood.
The Girl Scouts have partnered with Partake to launch 'Sparkables,' an allergy-friendly and gluten-free cookie. The product is manufactured in a dedicated facility free of the top nine food allergens to ensure safety for consumers with dietary restrictions.
The FDA granted Fast Track designation to Aravax for its lead product, PVX108, which is being developed as a disease-modifying immunotherapy for peanut allergy.
This proposed legislation seeks to expand the legal definition of major food allergens to include galactose-alpha-1,3-galactose (alpha-gal), which would mandate its inclusion on food labels to protect affected consumers.
This summary reviews ten significant advancements in food allergy research from 2025, including new pathways for treating anaphylaxis and developments in managing acquired allergies.
A study analyzing a 2023 national survey found that 70% of U.S. adults have no prior knowledge of alpha-gal syndrome. The findings underscore a significant need for public education regarding tick bite prevention and the risks of this allergy.
A study presented at the 2026 AAAAI Annual Meeting reveals that over 75% of children with food allergies are allergic to multiple foods. The findings highlight the need for more comprehensive pediatric management strategies for multi-food allergic patients.
Researchers have identified a specific subtype of eosinophilic esophagitis in pediatric patients that is linked to hypermobility and autonomic dysfunction.
A meta-analysis published in JAMA Pediatrics identifies eczema, delayed introduction of allergenic foods, and early antibiotic use as significant risk factors for the development of childhood food allergies.
This journal article explores the intersection of tick-borne sensitization and blood transfusion risks related to Alpha-gal syndrome. It serves as a clinical commentary on the evolving understanding of this condition.
Alpha-gal syndrome is an emerging IgE-mediated red meat allergy triggered by tick bites. The article highlights that the condition is often underdiagnosed due to its delayed and idiosyncratic symptoms.
NIAID reports on recent scientific progress regarding alpha-gal syndrome, including the discovery of rare human antibodies that may block allergic reactions to red meat. The agency notes that millions of Americans are bitten by ticks annually, which remains the primary driver of this allergy.
This report highlights recent fatal anaphylactic reactions, including the death of influencer Dominique Brown, to emphasize the ongoing risks of food allergies. The article calls for increased vigilance and better allergen communication in public settings.
A study presented at the 2026 AAAAI Annual Meeting reveals that 75.5% of children with food allergies are allergic to multiple foods. The findings suggest that clinicians should anticipate additional allergies based on a child's existing diagnosis to improve management.
Researchers have initiated a first-in-human clinical trial evaluating a novel microneedle stamp technology designed to deliver peanut immunotherapy through the skin.
Researchers have identified monoclonal antibodies that block patient IgE from binding to alpha-gal allergens. This discovery offers a potential new therapeutic pathway for managing alpha-gal syndrome by suppressing basophil activation.
Advocates and organizations like FARE are criticizing the FAA's recent proposed rule regarding epinephrine access on commercial aircraft, arguing it does not go far enough to ensure patient safety. The discussion centers on the need for mandatory autoinjectors and nasal epinephrine options in emergency medical kits.
A study from the University of Canterbury suggests that while cultured meat may have fewer traditional protein allergens, it could potentially trigger immune reactions in individuals with alpha-gal syndrome. The research highlights concerns regarding the carbohydrate galactose-alpha-1,3-galactose in lab-grown mammalian products.
A lawsuit has been filed against Whole Foods following an incident where a child suffered an anaphylactic reaction after consuming pizza from the store. The case highlights ongoing concerns regarding food allergen labeling and safety protocols.
Researchers are investigating the use of voice biomarkers as a non-invasive tool to detect early signs of exacerbations in patients with asthma and COPD.
This article features a discussion on Tolerance Induction Program (TIP) therapy, which aims to help patients achieve complete remission from food allergies through a structured treatment protocol.
SnackSafely.com warns the community about the proliferation of misleading or fraudulent reports regarding purported cures for food allergies, emphasizing the importance of relying on verified medical information.
Harbour BioMed announced positive Phase 2 clinical trial results for its TSLP-targeting antibody, HBM9378, and has initiated a Phase 3 study for the treatment of asthma.
The FDA provides comprehensive guidance on food allergen labeling, including the implementation of the FASTER Act which recognized sesame as the ninth major food allergen. The agency emphasizes that while therapeutic strategies are in development, strict avoidance remains the primary management for food allergies.
DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for the VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy for children aged 4-7 with peanut allergy. The BLA is supported by the Phase 3 VITESSE trial — the largest immunotherapy clinical trial to date for this population — and DBV has requested Priority Review. The FDA previously granted the patch Breakthrough Therapy Designation.
Delta Air Lines is introducing epinephrine auto-injectors into the emergency medical kits of all its aircraft over the next year, and Allegiant Air is also phasing in auto-injectors alongside its existing epinephrine vials. The voluntary safety upgrades come as the food allergy community urges the FAA to make epinephrine devices mandatory in airline medical kits before the October 5 public-comment deadline, with AAFA, FARE, the AMA, and Senators Duckworth and Schumer all pressing for a required modern epinephrine delivery device on every flight.
The Nadeau Lab provides updates on the SEAL study, which investigates the 'Atopic March' and the progression from eczema in infancy to other allergic conditions like food allergies.
Moonlight Therapeutics has received FDA clearance to begin clinical trials for MOON101, an intradermal allergen immunotherapy platform designed to desensitize individuals with peanut allergies.
FARE announced the launch of a new educational resource to support the food allergy community at the start of National Food Allergy Awareness Month.
The Asthma and Allergy Foundation of America provides guidance on managing asthma triggers during the colder months.
The National Eczema Association shares practical advice for patients to maintain skin health and handle eczema flare-ups.
The COPD Foundation released a video featuring experts discussing the management and long-term health implications of COPD.
Beyond Celiac emphasizes the autoimmune nature of celiac disease to improve public understanding and diagnosis.
CBS News reports on the rising threat of Alpha-gal syndrome, highlighting how tick bites from the lone star tick can trigger a severe allergy to red meat. The segment explores the impact on communities like Martha's Vineyard and provides expert advice on tick bite prevention.
Food Allergy Canada is urging all Canadian provinces to pass legislation requiring schools to stock unassigned epinephrine auto-injectors, following an incident where a 6-year-old Edmonton student with no known allergies had a first-time anaphylactic reaction and was saved by Alberta's 2020 stock epinephrine law. Alberta is currently the only province with such legislation.
An Australian study of 778 infants across 10 hospitals found that over a third of peanut oral food challenges were negative, enabling immediate delabeling and regular peanut consumption. Anaphylaxis occurred in 7.8% of all challenges. The study, published in J Allergy Clin Immunol Pract, supports supervised oral food challenge before starting peanut oral immunotherapy to confirm true allergy.
A new peanut allergy therapy, PVX108, has received FDA Fast Track designation. The treatment is currently being evaluated in an international Phase 2 clinical trial involving children and adolescents.
New federal legislation has been signed into law aimed at enhancing protections for children living with food allergies. The bill focuses on improving safety standards and support systems for students in educational environments.
FARE has called on the Federal Aviation Administration to mandate the inclusion of autoinjectors and nasal epinephrine administration options in emergency medical kits on aircraft. The organization argues that current proposed rule changes fail to adequately protect passengers with severe food allergies.
United Sugar Producers and Refiners recalled nearly 1.7 million pounds of brown and powdered sugar (Good & Gather, United, Crystal Sugar brands) across 8 Midwest states due to potential wheat kernel contamination. FDA assigned Class II risk on Sept. 21, 2026.
This article discusses the evolving landscape of food allergy treatments, specifically focusing on the introduction of biosimilars for Xolair, which is currently used to treat multiple food allergies.
The FDA has granted approval for clinical trials of a new anti-IgE antibody developed by LongBio, aimed at treating food allergies by targeting the underlying immune response.
FARE announced a partnership with Uber Eats to improve the accessibility of allergy-friendly dining options for the food allergy community.
Alpha-gal syndrome is a serious, potentially life-threatening allergy to a sugar molecule found in most mammals that can develop after a tick bite. The CDC notes that individuals with this condition may experience allergic reactions after consuming red meat or other products containing alpha-gal.
Sen. Mark Warner (D-VA) introduced two bills: the STOP TICKS Act to expand the federal Tick-Borne Disease Working Group and increase CDC grants, and the Alpha-Gal Allergen Inclusion Act to add alpha-gal to the federal major food allergen list for clear labeling. The House companion is sponsored by Rep. Jefferson Van Drew (R-NJ-02).
Aravax, a clinical-stage company, has secured $12 million in funding to advance its peptide-based immunotherapy for food allergies.
The Food Allergy Fund has committed funding to five new research projects aimed at improving the prediction, prevention, and treatment of food allergies.
Researchers at McMaster University have identified a specific memory B cell that appears to play a critical role in allergic reactions, offering a potential new target for therapy.
Moonlight Therapeutics has received FDA clearance to initiate clinical trials for MOON101, a new, patient-friendly treatment option for peanut allergy.
A new Teva antibody treatment has shown significant promise in reducing gut damage caused by gluten in patients with Celiac disease.
The FDA has accepted an Investigational New Drug application for OX640, a novel epinephrine nasal powder designed for the treatment of anaphylaxis.
Allergic Living reports on the FDA's approval of Xolair, the first medication authorized to reduce allergic reactions, including anaphylaxis, in patients with multiple food allergies. The article highlights how this treatment provides a new option for managing accidental allergen exposures.
Food Allergy Research & Education (FARE) is leading a national effort to coordinate strategies for alpha-gal syndrome. The initiative seeks to address gaps in diagnosis, care, and public health awareness regarding this emerging tick-borne allergy.
Melbourne-based biotech startup Aravax is developing a new therapeutic approach to treat food allergies. The company is advancing research aimed at modifying the immune response to common food allergens.
The FDA upgraded a recall of several Zapp's and Dirty potato chip varieties to Class I, its most serious classification, due to potential Salmonella contamination in a dry-milk-powder seasoning supplied by a third-party manufacturer. The recall affects more than 650,000 bags sold nationwide, including Bayou Blackened Ranch, Salt and Vinegar, Big Cheezy, Maui Onion, and Sour Cream & Onion varieties.
A study found that 8% to 13.9% of pediatric asthma patients screened in an academic clinic also presented with eosinophilic esophagitis.
Alpha-gal syndrome cases are increasing in Illinois as tick populations expand across the Midwest. Experts emphasize the need for avoidance of mammalian meat and the importance of carrying epinephrine for those affected by this tick-borne allergy.
Researchers at the Children's Hospital of Philadelphia have identified a specific allergen responsible for eosinophilic esophagitis (EoE) at the molecular level. This discovery marks a significant step in understanding the inflammatory disease of the esophagus.
An entomologist explains the mechanics of alpha-gal syndrome, a condition triggered by tick bites that causes an allergic reaction to red meat. The article notes that studies have linked ticks on six continents to the syndrome.
FARE is calling on the Federal Aviation Administration to mandate the inclusion of autoinjectors and nasal epinephrine in emergency medical kits on aircraft. The organization argues that current regulations leave food allergy patients at significant risk during air travel.
A CDC analysis of blood samples from 3,000 adults across 10 states suggests that a significantly higher number of people may be at risk for alpha-gal syndrome than previously estimated. The findings highlight the growing prevalence of this tick-borne meat allergy.
This report highlights the evolution of food allergy treatments, including the use of biologic agents like omalizumab (Xolair) to reduce IgE antibodies and the ongoing development of epicutaneous immunotherapy via Viaskin patches. These advancements aim to provide more effective desensitization and protection against accidental exposures.
This clinical trial investigates whether high maternal consumption of eggs and peanuts during pregnancy and lactation can effectively prevent the development of food allergies in infants. The study aims to provide evidence-based dietary guidance for expectant mothers.
Aquestive Therapeutics has resubmitted its NDA to the FDA for Anaphylm (dibutepinephrine) sublingual film, a needle-free, postage-stamp-sized epinephrine prodrug for treating Type I allergic reactions including anaphylaxis. The resubmission follows a January 2026 Complete Response Letter and is supported by positive human factors and pharmacokinetic study results showing reduced pouch-opening time and no protocol-defined use errors.
Research presented at the ACAAI Annual Scientific Meeting indicates that the severity, duration, and onset timing of eczema in children are significant factors in predicting whether they will outgrow food allergies. The study suggests eczema is not merely a co-occurring condition but one that influences the development and course of food allergies.
Researchers from Dartmouth Health found that patients with type O blood who have alpha-gal antibodies may experience severe allergic reactions when receiving blood plasma or platelets from type B or AB donors. The study analyzed over 550,000 transfusions to identify this risk.
Danone USA is recalling So Delicious Dairy Free Salted Caramel Cluster Non-Dairy Frozen Dessert pints with best-by dates on or before April 3, 2028, after customers reported small stones and hard foreign objects in the cashew inclusions. The pints were sold nationwide; consumers should not eat the product and can request a refund.
Delaware has implemented a landmark law requiring health insurance carriers to cover products containing measured amounts of peanut or egg protein for infants, shifting the focus toward proactive allergy prevention.
The FDA approved Xolair (omalizumab) as the first medication to help reduce the risk of serious allergic reactions, including anaphylaxis, in patients with one or more food allergies.
Research into using fecal microbiota transplantation from healthy donors to treat peanut allergies is progressing into Phase 2 clinical trials, exploring the role of gut bacteria in allergy management.
Data published in Annals indicates that Black and Hispanic children face significantly reduced odds of outgrowing food allergies compared to white children. The study highlights how socioeconomic factors and systemic disparities influence the long-term prognosis of pediatric food allergies.
A NIH-funded study published in Science Translational Medicine showed that fecal microbiota transplantation helped some participants increase their tolerance to peanuts, suggesting the gut microbiome could be a target for future allergy treatments.
This report examines the surge of interest in oral immunotherapy, detailing clinical trials aimed at desensitizing adults to peanuts and the changing landscape of allergy management.
Symptom-based screening in pediatric asthma and allergy clinics has identified a previously unrecognized high prevalence of eosinophilic esophagitis.
Researchers at Arizona State University have identified a gut pathway where leukotrienes, rather than histamine, drive severe allergic reactions. This discovery suggests that existing asthma medications could potentially be repurposed to prevent life-threatening anaphylaxis.
Following the FDA approval of neffy nasal spray, a new wave of needle-free epinephrine delivery systems is in development, including Anaphylm sublingual film (Aquestive, resubmitting NDA after a CRL), Hikma's epinephrine nasal spray (NDA accepted September 2026), and NS002 nasal powder (Nasus Pharma). These alternatives aim to expand access to emergency anaphylaxis treatment beyond traditional auto-injectors.
A TikTok video of a passenger panicking after eating a Snickers bar just before an in-flight announcement about a fellow passenger's severe nut allergy went viral, sparking conversation about airborne peanut allergy myths. Allergists clarified that airborne peanut allergy does not exist and the real risk is through ingestion and surface contact, not proximity to someone eating a peanut-containing product.
Whole Foods Market is recalling Fromagerie Coop de Mean Cabricharme cheese sold in 7 states because the product contains undeclared egg lysozyme, posing a serious or life-threatening allergic reaction risk to people with egg allergies. The cheese was sold at 18 Whole Foods stores in Arizona, California, Connecticut, Massachusetts, New Jersey, New York, and Rhode Island.
World Atopic Eczema Day, observed annually on September 14, raises awareness of atopic eczema (atopic dermatitis), a chronic inflammatory skin condition affecting millions worldwide. The day highlights the physical and emotional burden of the disease and advocates for better access to care, research, and support for patients and families living with eczema.
The Food Allergy Fund announced grant recipients under its Repurposing Challenge initiative to identify existing medications that can be repurposed to prevent or treat food anaphylaxis. The funding aims to accelerate treatments targeting the root biological mechanisms of severe food allergies.
FARE shares guidance and educational material advising parents and educators on what phrases to avoid when speaking to children living with food allergies.
Allergy & Asthma Network highlights medical research examining the intersection between celiac disease and respiratory health. Studies in allergy literature indicate individuals diagnosed with celiac disease may face an increased risk of developing asthma. The guidance outlines symptom overlap and immune pathways connecting gastrointestinal autoimmune conditions and allergic respiratory disease.
Delaware enacted landmark legislation requiring insurance support for early allergen introduction protocols to prevent childhood food allergies. Advocates project that early prevention will prevent life-threatening allergic reactions while saving millions in emergency healthcare expenditures. Advocates nationwide are leveraging this blueprint to advance similar preventive public health laws.
Alpha-gal syndrome reporting has expanded to thirteen states as lone star ticks and host populations broaden their geographic footprint across the United States. Clinicians and researchers emphasize increasing public awareness, tracking diagnostic delays, and recognizing potentially severe delayed anaphylactic reactions.
SnackSafely announced a new platform feature aimed at increasing ingredient transparency and allergen disclosure for packaged foods. The tool helps consumers navigating severe food allergies, celiac disease, and intolerances verify product safety beyond standard labeling. It allows families and schools to quickly screen foods for allergen cross-contact risks.
The Washington Post examines how adults can unexpectedly develop new food allergies later in life. Sensitivities can build slowly and may be amplified by co-factors such as exercise, alcohol, infections, or anti-inflammatory drugs.
NIAID highlights clinical advances in food allergy treatment, including oral immunotherapy, omalizumab for multiple food allergies, and skin patch desensitization for toddlers with peanut allergy.
A multi-institution study published in JAMA Internal Medicine finds that patients with tick-borne alpha-gal syndrome may face severe allergic reactions when receiving certain blood plasma or platelet transfusions. Researchers suggest the discovery could lead to altered transfusion practices in areas with high alpha-gal prevalence.
Food Allergy Canada debunks the dangerous myth that Benadryl (diphenhydramine) can replace epinephrine for anaphylaxis. Epinephrine is the first-line treatment; antihistamines do not reverse anaphylaxis symptoms and should only be given after epinephrine for comfort (itching). Newer non-drowsy antihistamines like Reactine, Claritin, or Aerius are recommended over Benadryl, which works more slowly and causes drowsiness.
Pirouette Pharma's OnePush is a disc-shaped, push-button auto-injector with a fully automatic, hidden needle that inserts, delivers, auto-retracts, and locks out in a fraction of a second — designed to reduce needle anxiety and improve adherence for at-home self-injection. The platform exceeds FDA emergency-use injector reliability guidance, is ISO-aligned for real-world conditions, and is U.S.-manufactured. Surveyed preference: 93% of patients and 88% of prescribers would switch to OnePush. All candidates remain investigational.
Girl Scouts of the USA partnered with Partake Foods to launch 'Girl Scout Sparkables' — the first top-9-allergen-free cookie in the iconic lineup. The oatmeal chocolate chip cookie with sprinkles is vegan, certified gluten-free, and made in Partake's dedicated facility. Available online starting January 2027, the cookie gives food-allergic Girl Scouts a safe option to finally enjoy alongside their peers.
Advocates and researchers warned that AI-generated misinformation and deliberate disinformation regarding food allergy treatments are creating health risks for patients. Food Allergy Canada and academic institutions addressed false claims, including fabricated stories regarding mRNA food allergy vaccines. Organizations urge families to vet emerging allergy therapy claims carefully through trusted and accredited medical sources.
The U.S. Equal Employment Opportunity Commission filed a lawsuit against Paycom alleging the company violated the Americans with Disabilities Act by terminating an employee instead of accommodating her severe food allergy. The EEOC noted that employers must explore reasonable workplace modifications rather than dismissing life-threatening medical needs. Legal advocates highlighted that food allergies are legally recognized disabilities requiring active employer cooperation.
Data presented at the European Respiratory Society International Congress demonstrated that dupilumab provided greater odds of clinical remission compared with other biologics in patients with type 2 severe asthma.
AAFA highlights that respiratory infections are major triggers that pose significant risks to the asthma community and discusses collaborative guidance to improve vaccine and care access.
SnackSafely reported on enhanced clinical guidance developed at Massachusetts General Hospital to identify signs of anaphylaxis in infants and toddlers. Because non-verbal children present subtle symptoms such as sudden behavioral changes or lethargy, updated criteria help caregivers and doctors intervene earlier. The recommendations emphasize prompt epinephrine administration.
The FDA granted priority review to omalizumab (Xolair) for reducing allergic reactions following accidental food exposure in pediatric and adult patients. The submission was supported by NIH/NIAID-funded Phase 3 OUtMATCH study results evaluating protection against multiple common food allergens. Priority review shortened the typical regulatory review timeframe.
Food allergy advocates voiced concern over a proposed FAA rule regarding commercial aircraft emergency medical kits that moves away from prescriptive medication lists. Advocates warn that eliminating explicit requirements could allow airlines to omit premeasured epinephrine auto-injectors from onboard kits. While the FAA issued non-binding guidance suggesting auto-injectors, critics argue passenger safety requires mandatory standards.
AAFA calls on followers to advocate for more than 100 million Americans living with asthma and allergic diseases during National Asthma and Allergy Awareness Month.
Health officials are working to raise awareness about alpha-gal syndrome, a tick-borne meat allergy linked to lone star tick bites that affects an estimated 450,000 Americans. Cases are expanding geographically from the southern and eastern US to northern regions such as Martha's Vineyard. The report highlights emerging symptom patterns, diagnosis challenges, and treatments like Xolair that help mitigate accidental exposure reactions.
The FDA approved Xolair (omalizumab) injection to reduce allergic reactions caused by accidental exposure in individuals aged 1 year and older with IgE-mediated food allergies. The historic approval offers multi-allergic families a preventive medication to mitigate severe outcomes like anaphylaxis. Clinical trial results verified that treated patients tolerated substantially higher amounts of key allergens such as peanut, milk, and egg.
Researchers at Massachusetts General Hospital have updated and refined clinical criteria to more reliably detect anaphylactic episodes in infants and toddlers. Diagnosing anaphylaxis in non-verbal children remains challenging due to atypical or subtle symptoms. The improved framework helps pediatricians and caregivers administer prompt, life-saving epinephrine treatment.
Food Allergy Research & Education (FARE) announced a $10 million grant initiative over four years to fund multidisciplinary proximal translational research aiming to bring food allergy breakthroughs into human studies faster.
AAFA highlights the impact of indoor allergen buildup in fabrics and advises washing clothes and bedding in water at 130°F or above to reduce environmental allergy and asthma triggers.
FARE issues an advocacy statement responding to the USDA final rule for WIC infant packages, urging policies that support early introduction of peanut products to prevent food allergies.
Health officials and experts raise awareness regarding alpha-gal syndrome, an emerging tick-borne red meat allergy. The report outlines rising case numbers associated with tick bites, particularly from lone star ticks, and highlights the ongoing need for public health recognition.
SnackSafely reported on emerging diagnostic advancements aimed at improving the accuracy of food allergy testing via specialized blood sampling. The new testing methodologies aim to minimize reliance on high-risk oral food challenges. This development offers families and clinicians safer tools to confirm food sensitivities.
NIAID outlined its ongoing strategic priority to research food allergies due to their rising prevalence and public health impact among children and adults. The agency detailed research tracks into risk factors, the nutritional strain of avoiding ubiquitous allergens, and underlying immune triggers. It highlights federal efforts to advance preventative strategies and innovative therapies.
A study highlighted by the American Academy of Allergy, Asthma & Immunology reveals that younger siblings of children who actively consume peanuts face an increased risk of developing a peanut allergy. The findings offer new insight into household environmental exposures and infant allergy sensitization. Researchers suggest tailored introductory strategies for families with older peanut-tolerant siblings.
Medical reporting highlights the geographic expansion of alpha-gal syndrome beyond historical regions in the Southeast and Mid-Atlantic. Clinicians are cautioned about non-traditional anaphylaxis presentations, including severe cardiovascular collapse without obvious respiratory distress. Emerging research also points to climate changes and deer populations expanding tick habitats.
New research released by the American Academy of Allergy, Asthma & Immunology explores how ultraviolet light influences environmental microbiomes and improves asthma outcomes in children. The study demonstrates environmental microbiome alterations as an actionable pathway for reducing pediatric asthma exacerbations. It provides critical context on outdoor environmental factors modifying allergic airway inflammation.
Efforts are accelerating to pass federal legislation known as the ADINA Act to require clear allergen transparency on medication labels. The bill seeks to protect individuals with severe food and ingredient allergies from hidden excipients in prescription and over-the-counter drugs.
Researchers at the University of Bern have developed a new diagnostic test designed to improve accuracy when detecting food allergies. Data showed significantly higher diagnostic accuracy compared to standard skin tests and specific IgE antibody blood measurements.
Research funded by the National Institutes of Health has revealed new insights into how the human digestive and immune systems differentiate between harmless food nutrients and potential allergens. The discoveries provide potential mechanisms for future preventative strategies and therapies.
An analysis evaluates ongoing research at Clemson University aimed at engineering genetically modified, reduced-allergen peanuts. The piece questions whether reducing allergenicity provides true safety for consumers with life-threatening allergies or risks creating a false sense of security.
Health experts examine the spread of the lone star tick and the resulting rise in alpha-gal syndrome, a tick-borne allergy to mammalian meat. The piece outlines risk levels across various American regions and provides guidance on tick bite prevention.
An NIAID-supported trial published in NEJM Evidence demonstrated that children with high-threshold peanut allergy could safely consume tablespoons of peanut butter via home-measured, store-bought dosing. Over an 18-month gradual escalation under intermittent medical monitoring, 100% of participating children reached tolerance of 9 grams of peanut protein without experiencing severe reactions. Sustained unresponsiveness persisted in nearly 87% of patients even after an eight-week complete cessation of peanuts.
Landmark findings from the LEAP-Trio trial established that consuming peanut products regularly from infancy until age 5 provides lasting protection against peanut allergy into adolescence. Long-term follow-up showed a 71% reduction in peanut allergy prevalence at age 13 among early consumers compared to avoiders, regardless of whether adolescents frequently consumed peanuts during intervening years. Health officials emphasized that early dietary introduction confers durable immune tolerance.
A large epidemiological review evaluating over 120,000 children across dozens of US pediatric clinics documented a 36 percent decline in overall early-childhood food allergies between 2012 and 2020. The decrease was largely attributed to a 43 percent drop in diagnosed peanut allergies following the adoption of infant dietary introduction guidelines. Researchers noted that egg has now overtaken peanut as the leading diagnosed food allergy in children under age three.
This peer-reviewed cohort study examined whether national clinical guidelines advocating early food allergen consumption translated to reduced allergy incidence at the primary care level. The authors found significant hazard ratio reductions for both peanut allergy and cumulative IgE-mediated food allergies in children monitored up to three years of age. Accompanying editorials stressed the public health importance of overcoming lingering parental and clinical hesitancy around infant feeding.
The FDA granted regulatory approval to Neffy (epinephrine nasal spray) 2 mg for emergency treatment of Type I allergic reactions, including life-threatening food-induced anaphylaxis. The approval represents the first non-injectable epinephrine delivery system available in the United States for adults and pediatric patients weighing 30 kg or more. Pharmacokinetic and pharmacodynamic data confirmed that the single-dose nasal spray delivers systemic epinephrine levels and physiological responses comparable to intramuscular auto-injectors.
NIH-sponsored Phase 3 OUtMATCH trial results revealed that extended omalizumab (Xolair) monotherapy outperformed multi-allergen oral immunotherapy in children allergic to peanuts and multiple other foods. By the trial's completion, 36% of omalizumab-treated patients tolerated substantial amounts of peanut plus two additional foods, compared with 19% on OIT. The difference was heavily driven by high adverse-reaction rates and treatment discontinuation among participants receiving oral immunotherapy.
In a Phase 2a clinical trial evaluating the investigational monoclonal antibody TEV ’408, researchers found that a single injection significantly protected patient intestinal lining during six weeks of daily gluten challenge. Treated patients also exhibited a dramatic reduction in inflammatory intraepithelial lymphocytes and lower gastrointestinal symptom scores compared to placebo. The study provides proof of concept for the first potential non-dietary therapeutic candidate to reduce gluten-induced damage.
Harvard Chan School spotlighted Dr. Kari Nadeau's appearance on CNN discussing a major clinical trial examining early preventative therapies in 800 infants with allergic skin conditions. The seven-year trial, which monitors high-risk babies to intercept food allergy pathways early, faced severe operational risks following federal research funding disruptions. Dr. Nadeau emphasized that abrupt pauses to clinical trials endanger pediatric patient safety and stall crucial preventative medicine.
NIAID-sponsored research demonstrates that oral immunotherapy can induce remission of peanut allergy in young children. The treatment involves administering gradually increasing amounts of peanut protein to desensitize patients.
The FDA announced a nationwide voluntary recall of three lots of Epinephrine Injection, USP 30 mg/30 mL (1 mg/mL) multi-dose vials by Ohio-based American Regent due to the presence of particulate matter (identified as nylon, cellulosic, acrylic, polyethylene, and glass) and a lack of sterility assurance. The recall follows customer complaints of leaking and cracked vials, which compromised sterility.
The FDA approved Xolair (omalizumab) injection for reducing allergic reactions, including anaphylaxis, caused by accidental exposure in people with multiple food allergies. Approval was supported by data from the Phase III OUtMATCH study funded by NIAID.
SnackSafely released comprehensive updates to its Safe Snack Guide catalog to support families and schools managing food allergies. The updated guide details allergen-safe products across multiple major allergens to prevent cross-contact in classrooms.
The article covers updates regarding the commercial market exit of an FDA-approved peanut allergy immunotherapy treatment. It discusses the implications for patients undergoing food allergy desensitization.
The AAAAI reported on findings surrounding a documented fatal case of alpha-gal syndrome to alert clinicians to atypical anaphylaxis presentations. The case underscores challenges in recognizing tick-borne meat allergy symptoms that can manifest hours after ingestion. Experts emphasized the critical need for prompt epinephrine administration and patient education regarding delayed allergic reactions.
An explainer on England's Benedict’s Law statutory guidance taking effect September 2026, requiring schools to implement whole-school allergy policies, staff training, Individual Healthcare Plans, and access to emergency adrenaline auto-injectors. Named for Benedict Blythe, who died aged 5 after an allergic reaction at school.
DBV Technologies, the French biopharmaceutical company developing the VIASKIN® Peanut Patch for food allergy immunotherapy, announced participation in three September 2026 investor conferences (Cantor Global Healthcare, Citi Biopharma, and H.C. Wainwright). The company is running clinical trials of its epicutaneous immunotherapy patch in toddlers and children with peanut allergy.
A Bristol student credits a school EpiPen with saving her life after a severe allergic reaction to a flapjack containing Brazil nuts, as England's new Benedict's Law requires all schools to stock adrenaline pens, train staff, and maintain an all-school allergy policy from September.
A family has initiated legal action against an airline following the tragic death of a teenager who suffered a fatal allergic reaction to a sandwich served during a flight. The lawsuit highlights critical gaps in airline allergen labeling and emergency response protocols.
The Asthma and Allergy Foundation of America released its 2026 report identifying cities with the highest asthma burden, emphasizing how poverty, air pollution, and healthcare barriers contribute to emergency room visits and mortality.
A study tracking over 1,300 children found that multi-food allergy is highly prevalent, suggesting that traditional single-allergy testing may be insufficient. The findings support more targeted screening to better manage complex pediatric health profiles.
The FDA has authorized the marketing of four new nicotine pouch products, a decision monitored closely by respiratory health experts regarding long-term lung impact.
This review highlights major advancements in food allergy management throughout 2024. The FDA's approval of omalizumab for the reduction of allergic reactions to accidental exposure to one or more foods was identified as the most significant development.
Recent research underscores that even with strict adherence to a gluten-free diet, individuals with celiac disease face significant ongoing challenges. The study explores the 'hidden burden' of the condition, emphasizing the need for better support and treatment options.
A study highlighted by Beyond Celiac suggests that children prescribed multiple courses of antibiotics may have an increased risk of developing celiac disease. Researchers found that antibiotics may affect proteins that maintain intestinal cell connections, though they caution against avoiding necessary medical treatments.
The AAFA released its 2026 Asthma Capitals report, identifying cities with the highest risk factors for asthma. The report highlights how environmental triggers and climate change are contributing to increased emergency room visits and mortality rates.
NIH researchers discovered rare monoclonal antibodies that act as a biological shield, blocking human allergic antibodies from binding to red meat allergens linked to alpha-gal syndrome (AGS) — an emerging tick-bite-associated condition with no current treatment or cure. The findings, published in the Journal of Clinical Investigation, emerged from malaria research and could inform the first targeted therapies for AGS, which has seen ~110,000 suspected U.S. cases since 2010.
NIH researchers have discovered rare monoclonal antibodies that can block human allergic antibodies from binding to red meat allergens, a breakthrough for alpha-gal syndrome — the tick-bite-associated condition with no current treatment or cure. The findings were published in the Journal of Clinical Investigation.
AstraZeneca and Amgen reported successful Phase III clinical trial results for tezepelumab, demonstrating its efficacy in treating patients with eosinophilic esophagitis.
The CDC provided a national update on the status of acute respiratory illnesses, noting that levels are currently low and decreasing.
FARE reports that patients and caregivers are encountering difficulties accessing the newly approved epinephrine nasal spray, neffy.
The Asthma and Allergy Foundation of America is recruiting participants for research studies focused on eczema treatments and management.
A research report and social update focusing on the unique presentation and management of anaphylaxis in the infant and toddler population.
The CDC provides regular updates on respiratory virus activity and safety guidance to prevent severe illness during peak seasons.
The network released a new comprehensive poster detailing various respiratory treatments, including inhalers and biologics, for patient education.
FARE hosted a webinar discussing the increasing prevalence of Alpha-gal syndrome, a food allergy to red meat caused by tick bites.
FARE announces the recommendation for approval of EURneffy, an epinephrine nasal spray, providing a needle-free alternative for treating anaphylaxis.
The FDA has granted Fast Track designation to a new, next-generation therapy aimed at treating peanut allergies, potentially accelerating its development and review process.
New research indicates that biological markers associated with persistent food allergies may be detectable in the placenta at the time of birth.
As the school year begins, experts emphasize the critical importance of updating emergency action plans for students with food allergies to ensure school staff are prepared for potential reactions.
New York lawmakers are advancing legislation to mandate access to stock epinephrine in childcare settings and require staff training to protect young children with food allergies.
The WHO released a summary highlighting the negative impact of tobacco use on asthma patients, emphasizing the necessity of comprehensive tobacco control to improve respiratory health outcomes.
A new Phase 2 clinical trial has been initiated to evaluate a potential therapeutic treatment for celiac disease, marking a step forward in research beyond the gluten-free diet.
This update highlights the results of the OUtMATCH clinical trial, led by researchers including Dr. Kari Nadeau, which demonstrated that omalizumab (Xolair) significantly increased the threshold of tolerance for multiple food allergens. The study provided the primary evidence for the subsequent FDA approval of the drug for food allergy management.
This report details the landmark approval of the needle-free emergency treatment Neffy, highlighting its portability and potential to reduce "needle phobia" barriers. The article includes commentary from medical experts on how the 2mg nasal dose compares to traditional auto-injectors.
CBS Mornings features medical contributor Dr. Céline Gounder explaining the mechanism of the new epinephrine nasal spray. The segment emphasizes that while the spray is needle-free, patients must still seek emergency medical monitoring after use, just as they would with an injection.
Coverage of the LEAP-Trio study results, detailing how early introduction of allergens is being adopted globally to stem the "allergy epidemic." The article highlights the significant reduction in peanut allergy cases among 12-year-olds who were part of the early-exposure group.
The NIAID released a formal statement regarding the FDA’s decision to approve Xolair for food allergies based on NIH-funded research. The drug is the first approved medication to reduce allergic reactions to multiple foods following accidental exposure in patients aged 1 year and older.
FARE announced that UberEats agreed to edit a Super Bowl advertisement that used life-threatening food allergies as a punchline following public advocacy.
The USAsthma Summit 2025 addressed the evolving landscape of asthma care, focusing on new therapies and persistent health disparities. Experts discussed the success of the PARTICS method, which improved outcomes for Black and Latinx patients by integrating anti-inflammatory treatment with reliever inhaler use.
Experts warn of the rise of AI-generated misinformation regarding food allergy 'cures' circulating on social media. Organizations like Food Allergy Canada are actively debunking these false claims to protect the community.
A large-scale study involving 2.8 million children has identified significant risk factors associated with the development of food allergies. The findings provide new insights into early-life predictors for allergic conditions.
The Protecting Children with Food Allergies Act mandates specialized training for school food service personnel to better recognize and respond to allergic reactions. The law aims to improve safety for students with undiagnosed or known food allergies.
AAFA shared expert guidance on identifying and avoiding common summer asthma triggers to help patients maintain better respiratory control.
The Asthma and Allergy Foundation of America is recruiting young adults with allergic diseases, including EoE and asthma, for a survey on managing health transitions.
The CDC issued guidance on basic preventive measures like handwashing and cough etiquette following a briefing on the upcoming respiratory illness season.
The FDA has cleared the GlutenID genetic test for celiac disease screening. Experts emphasize that while the test is a useful tool, it does not replace traditional diagnostic methods like biopsies and antibody tests performed by physicians.
A CDC report analyzing asthma prevalence in the U.S. shows that approximately 20.3 million adults live with the condition. While childhood asthma prevalence saw a significant decrease between 2010 and 2021, adult asthma prevalence increased significantly during the same period.
The 10th annual USAsthma Summit focused on advancements in asthma management and treatment. Key discussions included the integration of new medications and strategies to improve healthcare access for underserved communities.
The CDC provides updated guidance on Alpha-gal syndrome, a condition characterized by a meat allergy triggered by tick bites. The agency outlines the symptoms and the connection between specific tick species and the development of the allergy.
The Celiac Disease Foundation has awarded a $300,000 grant to support research into autoantibody formation in celiac disease. This funding aims to advance scientific understanding of the condition beyond the current standard of a strict gluten-free diet.
A large-scale study involving 2.8 million children has identified significant risk factors associated with the development of food allergies. The findings aim to help researchers and families better understand the origins of these conditions.
Advocates are expressing strong opposition to a proposed FAA rule that would allow airlines to choose whether or not to stock epinephrine devices on flights. The community argues this could compromise passenger safety.
The Asthma and Allergy Foundation of America is advocating for continued congressional funding for the CDC's National Asthma Control Program. The program is considered vital for managing asthma-related health outcomes across the country.
The FAO/WHO Codex Alimentarius Commission has officially adopted science-based guidance regarding the precautionary labeling of cereals containing gluten. This move aims to improve safety and clarity for individuals with celiac disease.
A study led by Dartmouth Health researchers suggests that alpha-gal syndrome may complicate the safety of blood plasma or platelet transfusions for affected patients. The condition, typically caused by tick bites, creates a chronic allergy to mammalian meat and byproducts.
A study from Imperial College London indicates that food allergy diagnoses in England have doubled over the last ten years. The research also highlights that a significant portion of individuals at risk for severe reactions do not carry epinephrine auto-injectors.
Amgen and AstraZeneca's anti-TSLP biologic Tezspire hit all primary and key secondary endpoints in the phase 3 Crossing trial for eosinophilic esophagitis (EoE), demonstrating significant improvements in histologic remission and swallowing difficulties through 52 weeks. If approved, Tezspire would become the second biologic specifically indicated for EoE, challenging Sanofi and Regeneron's Dupixent.
This feature marks the one-year anniversary of the first needle-free epinephrine treatment, examining its impact on patient compliance and emergency preparedness. Experts from the AAFA and Cleveland Clinic discuss how the availability of a nasal spray has reduced the "needle phobia" barrier in schools and public spaces.
The Nadeau Lab reports on the precarious status of longitudinal studies like Project Viva due to shifts in federal research funding. These studies are critical for understanding how environmental factors and early-life exposures contribute to the development of IgE-mediated food allergies.
Long-term data from the EPITOPE extension study shows that the investigational peanut patch continues to build tolerance over time. After three years of daily wear, a majority of participants could safely tolerate a significant accidental ingestion, marking a major milestone for epicutaneous immunotherapy (EPIT).
Researchers have launched a new clinical trial for the Viaskin Peanut patch specifically for infants aged 6 to 12 months. The study aims to leverage the "plasticity" of the infant immune system to induce long-term tolerance, potentially allowing for unrestricted peanut consumption later in life.
A technical report on the regulatory approval of Neffy, detailing the weight requirements (minimum 66 lbs) and the pharmacokinetics that satisfied the FDA’s safety concerns. The report also tracks the company's plans to seek approval for younger children.
A high-level FDA roundtable explored the "modern epidemic" of food allergies, focusing on shifting medical guidance from avoidance to early introduction. The panel highlighted that approximately 80,000 new peanut allergy cases were diagnosed in 2024 alone, emphasizing the need for standardizing infant feeding protocols.
NewsNation reports on the immediate availability of Neffy in US pharmacies, featuring interviews with allergists who call the approval a "turning point" in allergy management and emergency medicine.
CBS Mornings medical contributor Dr. Celine Gounder explains the mechanics of how the nasal spray delivers epinephrine as effectively as an injection. The segment highlights the $25 co-pay program designed to ensure broad access for insured families.
The Asthma and Allergy Foundation of America released its annual report identifying the most challenging U.S. cities for residents living with asthma based on health outcomes and environmental factors.
FARE announced a significant $10 million investment dedicated to proximal translational research aimed at accelerating the development of new treatments for food allergy patients.
FARE publicly criticized a Super Bowl advertisement for using food allergies as a comedic element, emphasizing that the condition is a serious, life-threatening disease.
The Allergy & Asthma Network shared an updated educational resource categorizing various respiratory treatments to help patients manage asthma and related conditions.
FARE reports that patients are encountering insurance barriers and prior authorization requirements when attempting to access the newly approved epinephrine nasal spray, Neffy.
A report on the clinical trial landscape indicates that over 20 companies are currently developing new therapeutic options for celiac disease, with several drugs in various phases of clinical testing.
The AAFA released its 2025 State Honor Roll, identifying significant gaps in state-level policies designed to support students with asthma and allergies in school environments.
The 2026 Allergy Capitals report from the AAFA details how climate change is contributing to longer and more intense pollen seasons, which significantly impact asthma and allergy management.
President Trump signed the bipartisan Protecting Children with Food Allergies Act into law, mandating allergy training for school food personnel. The legislation is designed to ensure staff can effectively recognize and respond to allergic reactions in school settings.
Researchers have identified a link between specific gut microbiome compositions and the development of FPIES, a non-IgE-mediated food allergy. The study suggests that early gut health may play a critical role in the manifestation of these allergies.
FARE released the Food Allergy Management in Schools (FAMS) report, providing updated recommendations for staff training, emergency preparedness, and allergen prevention. The guidance aims to enhance existing CDC protocols to better protect students with food allergies.
In recognition of National Asthma and Allergy Awareness Month, the AAFA is promoting community-based care strategies to improve health outcomes for individuals living with asthma. The initiative focuses on education and support systems to manage chronic respiratory conditions.
Research from Tampere University in Finland highlights progress in the development of the drug ZED1227 for celiac disease. The drug aims to address the underlying immune response to gluten.
A new report from the Harvard Law School Food Law and Policy Clinic warns that the proposed federal FRESH Act's sweeping preemption clause would supersede hundreds of state and local food safety laws — including additive bans, allergen warnings, restaurant inspections, cottage food laws, and contaminant testing — without requiring equivalent federal safeguards to replace them. The report, authored by Margaret Lynn and Emily Broad Leib, warns the bill would create regulatory vacuums, overload an under-resourced FDA, and weaken consumer-protection remedies, with advocates calling it a 'death star for state food policy.'
California enacted legislation requiring allergen disclosure in restaurants with at least 20 locations. The law, supported by the AAFA, is set to take effect in the summer of 2026.
Governor Gavin Newsom signed California's Elijah's Law on September 25, 2024, requiring state agencies to create an anaphylaxis policy for childcare centers. The policy allows facilities to opt-in to training and epinephrine administration protocols.
This report highlights that California is in the minority of states that mandate, rather than just allow, the stocking of epinephrine in schools, and notes the state's adaptation to newer epinephrine delivery systems.
Governor Gavin Newsom signed California's Elijah's Law on September 25, 2024, requiring state agencies to create anaphylaxis policies for daycare centers. The law authorizes centers to implement training for recognizing and treating anaphylaxis and managing epinephrine auto-injectors.
The Asthma and Allergy Foundation of America reports that California Governor Gavin Newsom signed legislation requiring allergen labeling in restaurants to improve safety for individuals with food allergies.
The AAFA is sponsoring SB 68, the ADDE Act, which would mandate that restaurants identify the top nine federally recognized allergens on their menus to align California with global best practices.
The Asthma and Allergy Foundation of America reports that Governor Newsom signed legislation requiring allergen labeling in California restaurants, marking a significant policy victory for food allergy safety.
California has enacted the ADDE Act, becoming the first state in the U.S. to require restaurants to share allergen information with customers. The law mandates that restaurants with 20 or more locations disclose the 'Top 9' allergens on their menus.
AAFA is sponsoring California SB 68, the Allergen Disclosure for Dining Experiences (ADDE) bill, which would require restaurants with 20 or more locations to provide written documentation of the top 9 allergens.
The Asthma and Allergy Foundation of America (AAFA) issued a letter of support for AB 2317, known as Elijah's Law, which aims to establish anaphylaxis policies in child daycare facilities to protect children with life-threatening food allergies.
Governor Gavin Newsom signed legislation enacting Elijah's Law in California. It ensures childcare facilities have mandated allergy training, emergency plans, and policies to protect children with food allergies.
The Asthma and Allergy Foundation of America (AAFA) is sponsoring California SB 68, known as the ADDE Bill, which aims to mandate the documentation of the top nine allergens in a written format for dining establishments.
Coverage details legislative efforts and debates surrounding California Assembly Bill 2042, sponsored by Assemblymember Carlos Villapudua, to mandate food allergy training and stock epinephrine in daycares before subsequent legislative efforts successfully passed. It highlights key policy benchmarks needed to safeguard medically vulnerable young children.
California enacted Elijah's Law, becoming the fifth state to mandate food allergy training and protocols in early childcare and daycare settings. The measure helps protect infants and toddlers from severe anaphylactic reactions while attending childcare facilities.
California Governor Gavin Newsom signed California's Elijah's Law into effect on September 25, 2024. The legislation mandates three state agencies to establish comprehensive anaphylaxis policies and emergency protocols for child care facilities.
Governor Gavin Newsom signed legislation championed by the Asthma and Allergy Foundation of America requiring food allergen disclosure in food facilities. The law aims to protect consumers dining out from severe allergic reactions through clearer transparency.
AAFA's policy scorecard details California's school health benchmarks for asthma and anaphylaxis emergency protocols. While California maintains emergency protocols for anaphylaxis and policies for school-based health centers, it only mandates asthma emergency protocols if schools choose to stock quick-relief medicine. The analysis highlights areas where state education and health statutes meet or fall short of recommended nationwide model policies.
California enacted Elijah's Law in September 2024, requiring childcare facilities to implement specific anaphylaxis policies to protect children with food allergies.
California passed the ADDE Act, a first-of-its-kind bill requiring allergen labeling in restaurants to protect the millions of residents living with food allergies. The legislation was supported by dozens of youth advocates who testified in Sacramento to improve dining safety.
FARE hosted a regional summit at Stanford University to provide education and community connection for caregivers and individuals living with food allergies.
California passed legislation requiring allergen labeling in restaurants, a move supported by youth advocates in Sacramento that aims to improve dining safety for individuals with food allergies.
California enacted Elijah's Law, which mandates anaphylaxis policies in licensed childcare facilities. The law allows facilities to opt into these safety protocols starting January 1, 2028.
California became the first state to mandate that chain restaurants share allergen information with customers. The legislation, co-sponsored by AAFA, sets a precedent for food allergen disclosure across the restaurant industry.
New York enacted legislation requiring public venues with a capacity of 1,000 or more to carry epinephrine auto-injectors and expanded Gio's Law to equip more first responders with the devices.
Governor Kathy Hochul signed a law making New York the first state to mandate that health insurers eliminate cost-sharing requirements, such as deductibles and copays, for asthma inhalers. This policy aims to improve affordability and access to essential respiratory medication for state residents.
New York lawmakers passed legislation in June 2026 to mandate that childcare centers maintain stock epinephrine and provide staff training. This bill strengthens the state's original Elijah's Law, which was the first of its kind in the nation.
This opinion piece highlights the critical importance of preventative care, such as vaccinations, in managing chronic respiratory and health conditions for patients seeing multiple specialists.
A New York City ordinance mandates that all city childcare centers and schools be equipped with stock epinephrine, serving as a model for statewide legislative efforts.
New York lawmakers passed legislation in June 2026 to strengthen Elijah's Law by requiring childcare centers to maintain a stock of epinephrine devices on-site. The bill awaits the governor's signature to mandate both the availability of the medication and staff training.
New York enacted legislation requiring large public venues like stadiums and ballparks to stock epinephrine auto-injectors and have trained personnel on-site. This makes New York the first state to mandate such requirements for these types of public facilities.
Governor Kathy Hochul signed legislation capping the cost of epinephrine auto-injectors at $100 per year for New York residents. The law aims to remove financial barriers for families managing life-threatening food allergies.
Following the original Elijah's Law, new 2026 legislative amendments were passed to mandate that childcare centers maintain stock epinephrine, moving beyond the previous opt-in model.
A new law signed by Governor Kathy Hochul mandates that asthma inhalers be available to New York residents at no cost through a price cap mechanism.
New York became the first state to require large public venues with a capacity of 1,000 or more to stock epinephrine auto-injectors and have trained personnel on-site.
New York enacted legislation mandating top-9 allergen labeling on foods pre-packaged on-site for retail sale (A6558), marking a first-in-the-nation standard. Concurrently, Governor Hochul signed A05392 to expand statutory definitions of epinephrine delivery devices to accommodate non-injectable options like nasal sprays in public and school health policies.
Tomorrow Lab and Belay collaborated on MedLocker, a wall-mounted smart station that keeps emergency medications like epinephrine auto-injectors (EpiPen, Auvi-Q) and naloxone secure yet accessible in under ten seconds — using a wand to disarm, with IoT alerts, a WiFi webcam, and a companion app. Designed for schools, daycares, universities, and sports venues, it supports compliance with New York's new law requiring large public-assembly venues (1,000+ occupancy) to maintain accessible emergency epinephrine and trained personnel.
The New York State Legislature passed legislation placing an insurance price cap of no more than $100 on a two-pack of epinephrine auto-injectors regardless of deductibles or copays. The measure was heavily advocated for by FARE, Allergy Advocates New York, and patient families to ensure affordable emergency medication.
Allergy Advocates New York commended legislative measures and governor actions addressing allergen labeling on pre-packaged foods and expanding definitions for epinephrine access. The initiative highlights state-level policies targeting protection against severe food allergies across New York communities.
New York City advanced legislation to require stock epinephrine in schools and childcare facilities, alongside trained personnel on-site. Advocates are also championing state bill S8587 to strengthen Elijah's Law statewide by requiring daycare stock epinephrine and incident tracking.
Advocacy groups are pushing for New York bills A771 and S7915, which would require insurers to cover nutritional supplements for early peanut and egg introduction. This policy aims to prevent the development of food allergies in infants based on recent medical research.
The Asthma and Allergy Foundation of America (AAFA) announced the enactment of Elijah's Law in Maryland, noting that the legislation was also being considered in Kansas and other states to improve safety in childcare centers.
Maryland enacted Elijah's Law, which mandates policies for childcare centers to manage food allergies and protect children from anaphylaxis. The article notes that similar legislation is being considered in other states, including Michigan and Missouri.
Maryland Governor Wes Moore signed Elijah's Law, which requires the state's education and health departments to develop guidelines for childcare centers to reduce food allergen exposure and mandates training for staff to recognize and respond to anaphylaxis.
Maryland enacted Elijah's Law, requiring child care centers to implement procedures to manage food allergies and reduce the risk of anaphylaxis. This legislation honors Elijah Silvera and mandates training and emergency protocols for child care providers.
This report details the enactment of Elijah's Law in Maryland, which mandates that childcare facilities implement policies to protect children with severe food allergies. It highlights the advocacy efforts of Thomas Silvera and the push for similar legislation in other states.
The signing of HB 1195 in Maryland establishes mandatory anaphylaxis protocols and training for over 5,000 licensed child care providers. The law is named after Elijah-Alavi Silvera and aims to protect children under age 5 from life-threatening allergic reactions.
The AAFA issued a letter of support for Maryland HB 181, which proposes requiring restaurants to document and disclose the top nine allergens to customers in a written format to improve food safety.
Governor Wes Moore signed legislation into law in Maryland requiring childcare centers to implement comprehensive food allergy management policies to protect children from anaphylaxis.
The Asthma and Allergy Foundation of America submitted a letter supporting Maryland House Bill 181, which aims to mandate the documentation of the top nine allergens in restaurants. The bill is designed to improve safety for individuals with food allergies by ensuring transparent allergen information.
Maryland enacted Elijah's Law, becoming the fourth state to implement policies mandating food allergy and anaphylaxis response protocols in early childcare and daycare settings. The measure takes effect July 1, 2024, and establishes guidelines for staff education and emergency recognition. Advocacy groups highlighted the milestone and urged remaining states to adopt similar early education protections.
Public Law 116-292 establishes federal grant preferences for states that encourage elementary and secondary schools to maintain comprehensive school-based asthma and allergy management programs. The statute sets standards for full-time school nursing or designated staff, individual student asthma and allergy action plans, and trigger-management training. It directly shapes state-level implementation of school health and emergency medication policies.
Maryland Governor Wes Moore signed HB 1195 (Elijah's Law) into law to establish anaphylaxis emergency guidelines and protections across the state's licensed child care facilities. The legislation protects over 29,000 Maryland children aged five and under living with potentially life-threatening food allergies.
FARE's official account confirmed the signing of Elijah's Law by Maryland Governor Wes Moore. The post highlights the advocacy efforts that led to Maryland joining Illinois, New York, and Virginia in passing this critical safety legislation.
Maryland Governor Wes Moore signed Elijah's Law on April 26, 2024, requiring childcare facilities to implement specific policies to protect children with food allergies.
Representative Debbie Dingell of Michigan introduced the Elijah E. Cummings Family Asthma Act in the U.S. House of Representatives to address asthma-related health policy.
The article highlights the advocacy work of Representative Debbie Dingell of Michigan in supporting legislative and policy efforts for asthma and allergy management.
Introduced by Representative Debbie Dingell of Michigan, this federal bill aims to address asthma-related health issues. The bill was referred to the Subcommittee on Health in September 2023.
The AAFA Michigan Chapter advocates for state legislation and regulatory actions to support those with asthma and allergies, including the HEAL project which addresses health inequities in asthma care.
Michigan is identified as one of the states where Elijah's Law legislation has been under consideration in the state house to mandate food allergy policies in childcare facilities.
Introduced by Representative Debbie Dingell of Michigan, this federal bill aims to address asthma-related health disparities and improve management policies, impacting national and state-level asthma advocacy.
The Asthma and Allergy Foundation of America outlines that Michigan is one of only ten states that mandates schools to stock undesignated epinephrine auto-injectors. The advocacy report highlights policy efforts to modernize state laws to permit newer FDA-approved formats, such as nasal epinephrine formulations.
Michigan legislators have debated bills requiring schools to stock epinephrine auto-injectors to prevent fatal anaphylactic reactions. Advocacy groups like the No Nuts Moms Group have pushed for these mandates to ensure emergency medication is available on-site.
Michigan Representative Debbie Dingell introduced this federal legislation to improve asthma care and research. The bill, named after the late Elijah Cummings, seeks to expand federal programs that address asthma disparities and environmental triggers.
Introduced by Rep. Debbie Dingell of Michigan, this federal bill seeks to address asthma-related health disparities and improve management resources for families.
This review notes that Alabama's school stock epinephrine law is unique in that it is only enforced if the state provides specific funding for the program. It highlights the variability in how states manage and fund emergency epinephrine access in K-12 schools.
The Allergy & Asthma Network reports that Alabama enacted HB295, which permits public venues to maintain stock epinephrine auto-injectors to protect individuals with known or first-time allergic reactions.
The AAFA 2025 State Honor Roll report indicates that Alabama allows but does not require schools to stock epinephrine. The state meets 5 of 27 policy standards, including protecting school personnel from liability for epinephrine administration and maintaining health histories for students with chronic conditions.
The report identifies Alabama, Florida, and Georgia as states that have not yet expanded Medicaid, which impacts access to affordable healthcare and asthma management for uninsured residents. The document advocates for policy changes to improve health outcomes in these regions.
This resource confirms that all 50 states, including Alabama, have enacted legislation protecting the rights of students to carry and use prescribed asthma medications in school settings.
This review confirms that all 50 states, including Alabama, have enacted legislation allowing schools to stock undesignated epinephrine auto-injectors for use during allergic or anaphylactic emergencies.
The Asthma and Allergy Foundation of America evaluated Alabama's statewide policies regarding school emergency readiness, asthma management, and allergy protocols. The report highlights areas where state standards succeed, such as medication policies, alongside gaps in nurse staffing ratios and indoor air quality standards. Advocacy leaders use the benchmark to promote targeted legislative updates in the state capital.
The Asthma and Allergy Foundation of America provides an advocacy score for Alabama, highlighting the state's current policy landscape regarding asthma and allergy management in public settings.
The Asthma and Allergy Foundation of America sent a letter supporting Alabama SB 351, which seeks to modernize school epinephrine stocking policies to include newer FDA-approved delivery systems beyond traditional auto-injectors.
The Asthma and Allergy Foundation of America announced the successful passage of Elijah's Law in Pennsylvania, which mandates food allergy policies in childcare settings.
Governor Josh Shapiro signed House Bill 928, making Pennsylvania the eighth state to enact Elijah's Law. The legislation mandates food allergy training and emergency preparedness in childcare settings.
Pennsylvania enacted House Bill 928, known as Elijah's Law, which mandates anaphylaxis training, epinephrine access, and parent education in childcare settings to protect children with food allergies.
Governor Josh Shapiro signed House Bill 928 into law, making Pennsylvania the eighth state to enact Elijah's Law, which mandates food allergy training and anaphylaxis protocols in childcare centers.
The American Academy of Allergy, Asthma & Immunology highlights its ongoing advocacy efforts to address the impact of asthma and allergies on public health and policy.
Pennsylvania enacted House Bill 803, enabling public schools to maintain emergency supplies of undesignated epinephrine and train personnel to administer the medication. The policy protects students experiencing first-time undiagnosed anaphylactic reactions on school grounds.
Pennsylvania lawmakers and advocates are advancing House Bill 77 to enhance restaurant safety for food-allergic patrons. The legislation mandates menu allergen notices, staff area educational posters, and customer disclaimers to disclose food allergies before ordering.
The Asthma and Allergy Foundation of America reports on legislative efforts across states to modernize epinephrine access beyond standard auto-injectors to include needle-free alternatives. The advocacy group provides policy toolkits to support pending state-level bills, entity stocking, and child care safety standards like Elijah's Law.
The AAFA State Honor Roll evaluates Tennessee's policies regarding school-based health services, noting the state's requirements for epinephrine stocking and the maintenance of health histories for students with chronic conditions.
Tennessee allows but does not require schools to stock epinephrine, and the state encourages local education agencies to conduct indoor air quality inspections in schools.
This report details the enactment of Tennessee legislation that facilitates the stocking of life-saving epinephrine in schools, following a national trend of states improving emergency allergy preparedness.
This report highlights Tennessee's legislative efforts to make it easier for schools to stock life-saving epinephrine to treat anaphylactic shock in students.
The Asthma and Allergy Foundation of America tracks Tennessee's legislative standards and statewide policies impacting asthma management and allergic condition preparedness in schools. The report assesses state measures including student self-carry rights and access to quick-relief medications across school systems.
The report highlights nationwide statutory updates modernizing school stock epinephrine legislation from auto-injectors to broader device-neutral language like 'epinephrine delivery systems'. This shift allows schools in states across the country to stock newly approved needle-free alternatives, such as epinephrine nasal sprays.
The AAFA submitted a letter to Tennessee lawmakers advocating for the modernization of emergency stock medication policies in schools to better protect students with food allergies and asthma.
The AAFA provided a letter of support for Tennessee HB 1550, advocating for school districts to have the flexibility to stock various FDA-approved epinephrine delivery systems.
This article reports on the expansion of Elijah's Law across the U.S., explicitly listing Illinois as one of the states that has already enacted this legislation to protect children in childcare centers.
The Childhood Anaphylactic Policy Act, known as Elijah's Law, was signed into law in Illinois on August 20, 2021. It mandates that the Illinois Department of Public Health establish anaphylaxis policies for school districts and child care facilities.
Illinois became the second state to enact Elijah's Law, mandating that daycare centers and schools implement strict anaphylaxis protocols. The law provides mandatory allergy training for staff to prevent fatal allergic reactions in early childhood settings.
The Asthma and Allergy Foundation of America highlighted state legislative progress on Elijah's Law, documenting Illinois' adoption of childcare food allergy management mandates. The national report assesses how states regulate food allergy emergency plans, staff training, and stock epinephrine in preschool and early learning environments. The findings support continuing legislative outreach to strengthen childcare safety standards across the country.
This CDC-published review confirms that all 50 states, including Illinois, have enacted laws allowing schools to stock undesignated epinephrine for use during allergic or anaphylactic reactions.
A 7-year-old Illinois boy suffered anaphylactic shock and was hospitalized for two days after coming into contact with pokeweed sap while doing yard work. The family was sent home with an EpiPen and eight medications, and the mother is now warning others about the dangers of the toxic plant.
The Asthma and Allergy Foundation of America submitted a formal letter of support for Missouri House Bill 2552, known as Elijah's Law, which aims to require child care programs to implement emergency protocols and staff training for managing severe food allergies.
The Asthma and Allergy Foundation of America identifies Missouri as one of the states where Elijah's Law, which requires childcare centers to implement food allergy management policies, is currently being considered by lawmakers.
Missouri lawmakers passed Elijah's Law, which requires early childcare providers to implement specific allergy protection and response plans to ensure the safety of children with food allergies.
This interview highlights enacted Missouri legislation allowing trained school personnel to administer life-saving epinephrine auto-injectors during anaphylactic emergencies. Advocates discuss how broadening authorization creates a stronger safety net for students unaware of life-threatening allergies.
Following the enactment of childcare allergy protections in Maryland, advocates reported building momentum for Elijah's Law legislation in Missouri. The Elijah-Alavi Foundation noted active collaboration with Missouri state representatives, including Emily Weber and Anthony Ealy, to advance and amend childcare anaphylaxis safety protocols.
In detailing advocacy milestones around stock epinephrine and childcare allergy protections, the report highlights that Elijah's Law has passed locally in Kansas City, Missouri. It also notes ongoing efforts by advocates to reintroduce and enact statewide childcare allergy safety mandates in Missouri's legislature.
Delaware became the first U.S. state to pass a law requiring insurance companies, including Medicaid, to cover early introduction food allergen supplements for infants. The law, signed by Governor John Carney, aims to help prevent the development of peanut and egg allergies.
Governor John Carney signed HB-274 into law, making Delaware the first state to require insurance companies to cover early introduction of food allergens. The law, effective January 1, 2026, provides parents with free peanut and egg allergen supplements to help prevent food allergies.
The article reports on state legislative actions establishing copay caps on epinephrine auto-injectors to ensure affordability for families managing severe food allergies. It notes that Delaware and Colorado are among the states that have led legislative pushes to limit patient out-of-pocket costs for emergency auto-injectors.
Delaware became the first U.S. state to pass legislation (HB-274) requiring insurance coverage for early food allergen introduction supplements, such as peanut and egg, to help prevent the development of allergies in infants.
Delaware passed House Bill 95, making it the second state to require insurance plans to cover epinephrine auto-injectors for children and teens, significantly improving affordability for families.
The AAFA provides an assessment of Alaska's school policies regarding asthma and anaphylaxis. The report highlights current requirements for school health records and the availability of epinephrine in emergency situations.
Alaska has established statutes (17.22.010 and 14.30.141) that allow for stock epinephrine in K-12 schools and permit students to carry prescribed epinephrine.
This report outlines Alaska's school policies regarding chronic conditions, noting that the state mandates schools to maintain records for students with asthma and anaphylaxis. It also confirms that Alaska requires schools to have procedures for stocking and administering epinephrine.
Advocacy groups have initiated discussions with Alaska state representatives regarding the implementation of Elijah's Law. The proposed policy focuses on requiring childcare facilities to implement anaphylaxis prevention training and emergency response plans to protect children with food allergies.
The Iola Register profiles Dorothy Sparks, executive director of Hope Unlimited in Iola, Kansas, who was diagnosed with alpha-gal syndrome in July 2023 after a persistent rash, exhaustion and stomach pain led her to seek care. The tick-associated allergy to mammal-derived ingredients now shapes her diet and daily routine, from checking food labels to avoiding everyday products such as body lotion. The story notes she is one of many people in southeast Kansas navigating the condition years after diagnosis.
This advocacy resource identifies Kansas as one of the states where Elijah's Law legislation has been introduced to improve food allergy safety standards in childcare settings.
This article discusses the momentum of Elijah's Law, which mandates food allergy policies in child care centers. It notes that similar legislation has been introduced or considered in several states, including Kansas.
The Asthma and Allergy Foundation of America issued a letter in support of Kansas Senate Bill 328, which aims to modernize emergency preparedness in schools by allowing access to all FDA-approved forms of epinephrine, including nasal sprays.
Wisconsin Governor Tony Evers signed legislation updating the state's stock epinephrine law to allow schools to stock all FDA-approved forms of epinephrine delivery systems, including nasal sprays.
Wisconsin enacted "Dillon's Law" updates (2025 Act 17/existing revisions), which allow schools to stock all FDA-approved epinephrine delivery systems, including nasal sprays. This legislation broadens the state's existing stock epinephrine law to ensure emergency medication is more accessible and easier to administer in schools and other public entities.
Governor Tony Evers signed legislation expanding the availability of epinephrine in schools and other public spaces, marking a significant update to Wisconsin's existing stock epinephrine policy.
Wisconsin updated Dillon's Law to become the first state permitting schools and public venues to stock all FDA-approved epinephrine delivery systems, including nasal sprays and sublingual forms. The measure expands the definition beyond auto-injectors and enables trained personnel to administer non-patient-specific emergency doses.
This report on school epinephrine stocking laws identifies Hawaii as the only state in the U.S. that had not yet passed a school epinephrine stocking law as of the publication date.
The Asthma and Allergy Foundation of America identifies Hawaii as the only state in the country currently lacking epinephrine stocking policies for schools. The organization is actively calling on state lawmakers to implement requirements for schools to stock FDA-approved epinephrine.
AAFA highlights national progress under the School Access to Emergency Epinephrine Act, noting that nearly every state except Hawaii has enacted a school epinephrine stocking law. The organization details ongoing advocacy gaps and policy efforts needed to bring stock epinephrine legislation to Hawaii.
The AAFA issued a formal letter of support for Arkansas HB 1817, known as Elijah's Law, which mandates that childcare providers implement emergency protocols and anaphylaxis treatment plans.
Governor Sarah Huckabee Sanders signed "Elijah's Law" (HB1817) into effect in April 2025, requiring childcare programs to follow stringent guidelines for preventing and responding to severe food allergy reactions.
The AAFA evaluates Arkansas's school policies, noting that the state meets 9 of 12 policy standards regarding medication and treatment, including requirements for epinephrine stocking and liability protections for school personnel.
Connecticut Attorney General William Tong announced an $8 million settlement with pharmaceutical company Mylan over allegations it illegally inflated EpiPen prices in violation of state antitrust and consumer protection laws. Mylan will provide Connecticut with 10,000 free EpiPens (5,000 two-packs) to expand equitable access, distributed by the state Department of Public Health to 30 Federally Qualified Health Centers. Mylan denies any wrongdoing.
Connecticut was one of only two states to make the 2025 AAFA State Honor Roll for meeting at least 22 of 27 core policies regarding allergy and asthma management in schools. The report highlights the state's commitment to school-based health policies compared to other regions.
The Asthma and Allergy Foundation of America recognized Connecticut on its State Honor Roll for enacting exemplary school policies addressing asthma and allergic diseases. Connecticut met key policy standards including student medication self-carry laws and supportive school healthcare management benchmarks.
Walt Disney World is updating its menu tree nut definition to align with the FDA's revised guidance, which removes coconut, chestnut, hickory, and several other nuts from the major allergen list. Guests with allergies to those newly excluded items should read ingredient labels carefully, as items labeled 'tree nut free' will no longer exclude them.
A new state law requires public and charter elementary schools to train employees to recognize life-threatening allergic reactions and administer emergency medication, extending protections to before- and after-school programs.
A state law passed in 2025 requires elementary schools to train staff on recognizing and treating life-threatening allergic reactions, extending protections to before- and after-school programs.
The "Arizona Healthy Schools Act" (A.R.S. 15-242.01) went into effect for the 2026-27 school year, prohibiting public schools from serving or selling foods containing specific additives (such as certain dyes and potassium bromate) during the school day to promote a healthier food environment.
This law established the framework for Arizona schools to stock and administer emergency epinephrine. It includes Good Samaritan immunity for trained staff.
A comprehensive review of state laws identifies Arizona as a state that designates medical and school health professionals, along with nursing associations, as key stakeholders in developing stock epinephrine procedures. The study highlights Arizona's collaborative approach to implementing emergency allergy protocols in schools.
Advocates are urging policymakers to address high ozone levels, which disproportionately trigger asthma attacks and exacerbate respiratory conditions for Coloradans, especially children.
The AAAAI outlines its national advocacy efforts for policies that support allergy and immunology practices. This includes lobbying for fair reimbursement and reduced administrative burdens for providers treating patients with asthma and allergies in states like Colorado.
Advocacy organizations across the nation are working to update existing state stock epinephrine statutes to modern 'epinephrine delivery device' language. The policy updates ensure school districts can legally stock needle-free epinephrine alternatives like nasal sprays.
This report evaluates Idaho's school policies regarding asthma and allergy management. It notes that while Idaho requires schools to maintain health records for students with chronic conditions, it lacks certain emergency protocol mandates for asthma and anaphylaxis.
The Asthma and Allergy Foundation of America evaluated Idaho's policy landscape, noting the state meets 11 of 23 core policy standards regarding asthma and allergy management.
The Asthma and Allergy Foundation of America's 2025 State Honor Roll report evaluates Idaho's progress in school-based health policies. The report notes that while Idaho requires districts to maintain asthma and anaphylaxis medication policies, it currently lacks mandates for stocking emergency epinephrine or albuterol in schools.
Following a tragic incident, Virginia passed a law requiring all schools to stock epinephrine, setting a precedent for other states to follow suit with similar legislation.
The Virginia Department of Health's 2026 food regulation updates take effect September 10, 2026, requiring food establishments to disclose allergens on menus using words, icons, or numbers with a guest legend, and providing a standardized Food Allergen Notice. The update also introduces a new produce safety regulatory program covering the growing, packing, holding, and dissemination of produce grown on farms.
The Asthma and Allergy Foundation of America reported on state-level child care policy wins, confirming Virginia enacted Elijah's Law on April 11, 2022. The legislation establishes comprehensive food allergy safety guidelines and emergency anaphylaxis preparedness for child day care centers.
Laura's Law was signed in Massachusetts to improve emergency department standards for signage and accessibility following the death of Laura Levis. The bill was supported by advocacy efforts from the Asthma and Allergy Foundation of America.
Legislators in Massachusetts have considered a bill that would mandate food allergy training for restaurant staff to improve safety for customers with severe allergies. The proposed policy aims to build upon existing state protections for individuals with food allergies.
Massachusetts meets 20 of 23 core policy standards for asthma and allergy management in schools. The state allows for the stocking of asthma quick-relief medicine, though administration is currently restricted to licensed healthcare professionals.
The AAFA provides a scorecard for Texas, noting that the state allows but does not mandate the stocking of epinephrine in schools. The report evaluates state policies regarding the management of chronic conditions like asthma and anaphylaxis in educational settings.
AAFA's nationwide Elijah's Law initiative benchmarks state child care regulations against standards for allergy management, emergency action plans, and staff training. The report provides advocacy toolkits and model legislation to prompt state legislatures, including Texas, to enact comprehensive childcare allergy safety policies.
The AAFA reports that North Dakota allows, but does not mandate, the stocking of epinephrine in schools. The state currently lacks specific requirements for school-based chronic condition health histories and funding for stock medications.
AAFA highlights national and state legislative achievements under the federal School-Based Allergies and Asthma Management Program Act, which directs grant preferences to states establishing comprehensive school allergy and asthma policies. The report encourages state legislatures, including North Dakota, to align policies with state honor roll benchmarks for emergency action plans and student health tracking.
The School-Based Allergies and Asthma Management Program Act was signed into law, providing federal grant preferences to states that implement comprehensive allergy and asthma management programs in schools. This federal policy encourages states to adopt standards for student action plans and staff training.
The District of Columbia has historically been recognized for meeting core policy standards for school-based asthma and allergy management, including provisions for stock epinephrine. Official guidance and policies in the District focus on maintaining emergency response protocols, training staff, and ensuring that students with chronic conditions have access to necessary life-saving medications.
The AAFA 2025 State Honor Roll evaluates South Dakota's school policies, noting the state meets 4 of 27 policy standards regarding student self-carry rights and anaphylaxis management.
South Dakota is recognized for meeting core policy standards regarding the self-administration of asthma and anaphylaxis medication in schools. The state also provides funding for staff training in food allergy awareness and asthma management programs.
Maine enacted legislation to expand the definition of allowable epinephrine devices in schools and summer camps. The law allows for more cost-effective, evidence-based delivery methods to be used in emergency allergy situations.
Kids With Food Allergies outlines advocacy campaigns to expand Elijah's Law across remaining states, including Maine, to protect toddlers and children with food allergies in child care settings. The initiative provides model bill language and toolkits for advocates to lobby state legislators for mandatory food allergy management protocols.
Flowers Foods, Inc. is recalling Nature's Own Hawaiian Bread (20 oz and 40 oz 2-pack) due to undeclared milk allergen. The affected product was distributed to retail customers in Arkansas, Louisiana, New Mexico, Oklahoma, and Texas. People with a milk allergy or severe sensitivity risk an allergic reaction if they consume the product.
The Asthma and Allergy Foundation of America supports Rhode Island bill S2855, which would require schools to stock both undesignated epinephrine and asthma rescue inhalers.
This report discusses legislative efforts in New Jersey to mandate that schools stock epinephrine injectors, highlighting the advocacy of groups like the New Jersey Food Allergy and Anaphylaxis Coalition to improve student safety.
AAFA's State Honor Roll review benchmarks Wyoming's school policy framework, highlighting policy gaps regarding mandates for school nurses, stock epinephrine, and stock asthma rescue medication. The report forms the basis of advocacy campaigns targeted at Wyoming state lawmakers to adopt comprehensive school allergy protocols.
AAFA evaluates South Carolina's public health policy standards for school-based asthma and allergy management. The report details requirements for district medication protocols and health records while highlighting opportunities to implement stock albuterol and stock epinephrine programs.
Allergy & Asthma Network documents state legislative measures permitting schools to maintain stock albuterol inhalers for students experiencing respiratory distress. Indiana is highlighted among the states that have established laws enabling schools to obtain a prescription and administer stock albuterol.
AAFA released its 2025 State Honor Roll report evaluating state policies across the country for asthma and allergy preparedness in schools, identifying major gaps in school nurse mandates and medication access. The advocacy organization outlines legislative opportunities for states like Ohio to expand school stocking of albuterol and comprehensive allergy management.
FARE outlines school epinephrine legislation across the United States, tracking state laws that require or allow schools to maintain undesignated epinephrine auto-injectors. North Carolina is tracked within the framework of states providing legislative authority for schools to stock and administer emergency epinephrine to treat anaphylaxis. The resource supports continued advocacy for comprehensive school access to life-saving allergy medications.
A collaborative initiative between the Utah School Nurses Association, Utah Food Allergy Network, and Utah Department of Health trained school staff to recognize and respond to anaphylaxis via a web-based curriculum. From 2012–2023, the training was completed 5,759 times across 421 Utah schools, resulting in a 245% increase in schools with stock epinephrine — addressing a critical gap in a state with inadequate school nurse coverage.
Nebraska is among the states that have passed laws or guidelines permitting schools to stock albuterol for students in respiratory distress. This legislation is part of a broader effort to improve school-based management of chronic respiratory conditions.
While we strive for accuracy, information may change over time. Always double-check and verify against official sources before relying on it.
